

ALLEGATO A

UNIVERSITÀ DEGLI STUDI DI MILANO

Procedura di selezione per la chiamata a professore di I fascia da ricoprire ai sensi dell'art. 18, comma 1, della Legge n. 240/2010 per il settore concorsuale _____06/C1 - Chirurgia Generale_____,
(settore scientifico-disciplinare _____MED/18 - Chirurgia Generale_____)
presso il Dipartimento di _____Ematologia ed Emato-Oncologia_____,
(avviso bando pubblicato sulla G.U. n. __61__ del __2/8/2019__) - Codice concorso __4178__

Dr. Alessandro Gronchi

CURRICULUM VITAE

INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)

COGNOME	GRONCHI
NOME	ALESSANDRO
DATA DI NASCITA	11/06/1968

INSERIRE IL PROPRIO CURRICULUM (non eccedente le 30 pagine)

1. Titoli di studio

- Laurea in Medicina e Chirurgia presso l'Università Statale di Milano il 5/11/1992 con la votazione di 110/110 e lode
- Abilitazione all'esercizio professionale presso l'Università Statale di Milano nel Novembre 1992
- Iscrizione all'Albo dei Medici Chirurghi di Milano al n. 32162 dal 23/1/1993 a tutt'oggi
- Specializzazione in Chirurgia d'Urgenza e Pronto Soccorso presso l'Università Statale di Milano il 3/7/1997 con la votazione di 70/70. Tale specialità è equipollente a quella di Chirurgia Generale secondo il decreto ministeriale della Sanità - 30 gennaio 1998 e seguenti.
- Conoscenza della lingua Inglese scritta, comprensione orale e parlata di livello avanzato (autocertificazione di livello C1).

2. Titoli di Carriera

- 1/7/1994 - 30/6/1996: Assistente a tempo pieno di Chirurgia Generale presso il St. Mary's Hospital - Lacor - Gulu - Uganda
- 1/1/1998 - 30/6/1999: Ricercatore presso la Fondazione IRCCS Istituto Nazionale dei Tumori - Via Venezian 1 Milano - Italia (EX ART. 36 DPR 617/80);
- 1/10/1999 - 30/10/2006: Dirigente Medico I livello di Chirurgia Generale presso la Struttura Complessa (SC) Chirurgia Generale 4 (Chirurgia Melanomi - Sarcomi) - Fondazione IRCCS Istituto Nazionale dei Tumori - Via Venezian 1 Milano - Italia
- 1/11/2006 - 30/6/2011: Dirigente Medico I livello di Chirurgia Generale con incarico di alta specialità per la Chirurgia dei Sarcomi presso la SC Chirurgia Generale 4 (Chirurgia Melanomi - Sarcomi) - Fondazione IRCCS Istituto Nazionale dei Tumori - Via Venezian 1 Milano - Italia
- 1/7/2011 - tutt'oggi: Dirigente medico I livello responsabile della Struttura Semplice Chirurgia dei Sarcomi presso la SC Chirurgia Generale 4 (Chirurgia Melanomi - Sarcomi) - Fondazione IRCCS Istituto Nazionale dei Tumori - Via Venezian 1 Milano - Italia

3. Interventi chirurgici 1/6/2010 - 31/7/2019

- 1978 interventi chirurgici, 996 come primo operatore e 982 come assistente. Tali interventi hanno comportato l'esecuzione di 5456 procedure, 2965 come primo operatore e 2491 come assistente. L'elenco di tali procedure vidimato dalla direzione sanitaria della Fondazione IRCCS Istituto Nazionale

dei Tumori - Milano è riportato in fondo al CV.

4. Attività Didattica

- Tutore della Scuola di Specializzazione di Chirurgia Generale dell'Università Statale di Milano per gli A.A. 2009/2010, 2010/2011, 2011/2012, 2012/2013, 2013/2014, 2014/2015, 2015/2016.
- Tutore della Scuola di Specializzazione di Ortopedia e Traumatologia, relativamente al tronco comune per l'insegnamento della Chirurgia Generale/Oncologica, dell'Università Milano - Bicocca per gli A.A. 2005/2006, 2006/2007, 2007/2008, 2008/2009, 2009/2010, 2010/2011, 2011/2012, 2012/2013, 2013/2014, 2014/2015, 2015/2016, 2016/2017, 2017/2018.
- Professore a contratto gratuito a tempo determinato, dell'insegnamento di Chirurgia epato-bilio-pancreatica, modulo di chirurgia oncologica 1, didattica pratica SSD - MED/18 (ore 3) della Scuola di specializzazione in Chirurgia Generale dell'Università Statale di Milano per gli A.A. 2016/2017 e 2017/2018.
- Tutore per il periodo elettivo sulla chirurgia dei sarcomi nel percorso di Fellowship in Chirurgia Oncologica dell'Università di Toronto - Canada dal 1-1-2016 a tutt'oggi (certificazione in fondo al CV)
- Tutore per il periodo elettivo sulla chirurgia dei sarcomi nel percorso di Fellowship in Chirurgia Oncologica dell'Università di Ottawa - Canada dal 1-1-2019 a tutt'oggi (certificazione in fondo al CV)
- Tutore del dottorato di ricerca in Oncologia Clinica e Sperimentale ed Immunologia del Dr. Sandro Pasquali presso il dipartimento di scienze chirurgiche oncologiche e gastroenterologiche dell'Università di Padova dal 9/2016 al 2/2019.
- Direttore del Corso di Perfezionamento Universitario "Protocolli di trattamento dei Sarcomi delle Parti Molli dell'Adulto" presso l'Università Statale di Milano il 16/09/2005
- Docente del corso residenziale promosso da Accademia di Medicina sui sarcomi a Milano il 21-23/3/2005
- Docente del corso residenziale promosso da Accademia di Medicina dal titolo "I tumori delle parti molli: un approccio diagnostico integrato" a Treviso del 29/11-02/12/2006, 14-17/05/2007, 18-21/02/2008, 06-08/04/2009, 12-14/05/2010, 11-13/4/2011
- Docente dell'European Society of Medical Oncology (ESMO) International Symposium on Sarcomas and GIST tenutosi a Milano il 17-18/05/2006, 13-14/05/2008, 09-10/03/2010, 09-10/03/2012, 18-19/02/2014, 15-16/02/2016, 05-06/02/2018.
- Docente dell'Advanced Course in Bone and Soft Tissue Sarcoma, tenutosi ad Erice il 04-05/02/2011
- Docente del Corso Avanzato della European School of Oncology dal titolo "Rare Solid Cancers: an introduction" tenutosi a Stresa il 31/3-1/4/2011
- Docente del 2° Corso Educazionale sui Tumori Rari, tenutosi a Mazara del Vallo il 3-5/5/2012.
- Docente del Corso Educazionale Regionale sui Sarcomi dei Tessuti Molli tenutosi a Ragusa il 9-10/05/2014
- Docente del Corso di Perfezionamento Universitario dell'Università Statale di Milano "l'Ecoendoscopia con agoaspirato in ambito oncologico" tenutosi a Milano il 25-26/01/2017
- Docente del Corso Avanzato della European School of Oncology dal titolo "2nd ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers" tenutosi a Milano il 02-04/12/2017
- Docente del Post-Graduate University Course in Clinical Oncology sui Sarcomi, promosso dall'Università Statale di Milano e dalla European School of Oncology tenutosi a Milano il 22-26/01/2018
- Docente del Corso "Hot Topics in Therapeutic and Palliative endoscopy in Oncology 2018", tenutosi a Milano il 13-14/09/2018.
- Docente del Corso residenziale in Oncologia Clinica sui Sarcomi promosso dalla European School of Oncology tenutosi ad Inveruno il 3-5/07/2019
- Direttore del Masterclass Europeo sulla Chirurgia dei GIST e dei Sarcomi tenutosi all'Institut Gustave Roussy - Villejuif il 24-25/11/2011, 24-25/10/2012, 13-14/10/2014, ed all'Institut Curie - Paris il 15-16/11/2016.
- Direttore di RESURGE, corso teorico/pratico sui sarcomi retroperitoneali, promosso dalla Società Italiana di Chirurgia Oncologica e dall'Italian Sarcoma Group, tenutosi a Milano il 18-19/4/2016, 27-28/3/2017, 08-09/03/2018, 25-26/10/2018, 11-12/04/2019.
- Direttore del Corso promosso da Accademia di Medicina sui Sarcomi retroperitoneali tenutosi a Milano il 7/10/2015, 21/9/2016, 5/10/2017, 19/9/2018.
- Direttore del Corso promosso da Accademia di Medicina dal titolo "Building Expertise on Sarcoma Tumor" tenutosi a Roma il 2/10/2018.
- Ha ospitato dal 2005 57 colleghi e fellow internazionali, da Europa, Canada, Stati Uniti, Giappone, Australia e Sud-America. L'elenco aggiornato a 2/2019 si trova al seguente link: https://www.istitutotumori.mi.it/documents/848032/1069845/VP_2019_02.pdf/258b2a39-036a-d4ee-5f6c-30d9fc39e78b

5. Attività di ricerca e pubblicazioni scientifiche

- Elenco completo pubblicazioni censite da Medline in inglese

1. Bozzetti F., Bertario L., Rossetti C., Gennari L., Andreola S., Baratti D., **Gronchi A.** Surgical treatment of locally recurrent rectal carcinoma. *Disease of the Colon Rectum* 1997; 40 (12): 1421-1424.
2. Bozzetti F., Baratti D., Andreola S., Zucali R., Schiavo M., Spinelli P., **Gronchi A.**, Valvo F., Mariani L., Gennari L. Preoperative Radiation Therapy for T2-T3 cancers of the middle-to-lower rectum. *Cancer* 1999; 86 (3): 398-404.
3. Azzarelli A., **Gronchi A.**, Bertulli R., Tesoro Tess J.D., Baratti D., Pennacchioli E., Dileo P., Rasponi A., Pilotti S., Casali P.G. Low-dose chemotherapy with Methotrexate and Vinblastine for advanced aggressive fibromatosis. *Cancer* 2001, 92 (5): 1259-1264.
4. Mezzelani A., Mariani L., Tamborini E., Agus V., Riva C., Lo Vullo S., Fabbri A., Stumbo M., Azzarelli A., Casali P.G., **Gronchi A.**, Sozzi G., Pierotti M.A., Pilotti S. SYT-SSX fusion genes and prognosis in synovial sarcoma. *Br J of Cancer* 2001, 85 (10): 1535-9.
5. Ferrari A., Casanova M., Bisogno G., Mattke A., Meazza C., **Gronchi A.**, Cecchetto G., Fidani P., Kunz D., Treuner J., Carli M. Hemangiopericytoma in pediatric age: a report from the italian and german soft tissue sarcoma cooperative group. *Cancer* 2001, 92 (10): 2692-2698.
6. Tamborini E., Agus V., Perrone F., Papini D., Romanò R., Pasini B., **Gronchi A.**, Colecchia M., Rosai J., Pierotti M.A., Pilotti S. Lack of SYT-SSX fusion transcripts in malignant peripheral nerve sheath tumors on RT-PCR analysis of 38 archival cases. *Lab Invest.* 2002, 82 (5): 609-618.
7. Deraco M, **Gronchi A.**, Mazzaferro V, Inglese MG, Pennacchioli E, Kusamura S, Rizzi M, Anselmi RA Jr, Vaglini M. Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei. *Tumori.* 2002, 88(5):370-5.
8. **Gronchi A.**, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, Bertulli R, Fiore M, Olmi P, Santinami M, Rosai J. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. *J Clin Oncol.* 2003; 21(7):1390-7.
9. Baratti D, **Gronchi A.**, Pennacchioli E, Lozza L, Colecchia M, Fiore M, Santinami M. Chordoma: natural history and results in 28 patients treated at a single institution. *Ann Surg Oncol.* 2003; 10(3):291-6.
10. Ferrari A, Dileo P, Casanova M, Bertulli R , Meazza C, Gandola L, Navarria P, Collini P, **Gronchi A.**, Olmi P, Fossati-Bellani F, Casali PG. Rhabdomyosarcoma in adults: a retrospective analysis of 171 patients treated at a single institution. *Cancer* 2003; 98 (3): 571-580.
11. Collini P, Mezzelani A, Modena P, Dagrada P, Tamborini E, Luksch R, **Gronchi A.**, Navarria P, Sozzi G, Pilotti S. Evidence of neural differentiation in a case of post-therapy primitive neuroectodermal tumor/Ewing sarcoma of bone. *Am J Surg Pathol* 2003 Aug;27(8):1161-1166.
12. Deraco M, Kusamura S, **Gronchi A.** [Cytoreductive surgery (peritonectomy) and intraperitoneal hyperthermic chemotherapy: an innovative and effective approach to the treatment of pseudomyxoma peritonei]. *Tumori.* 2003 89(4 Suppl): 54-5.
13. Perrone F, Tabano S, Colombo F, Dagrada G, Birindelli S, **Gronchi A.**, Colecchia M, Pierotti MA and Pilotti S. p15INK4b, p14ARF and p16INK4a inactivation in sporadic and NF1-related Malignant Peripheral Nerve Sheath Tumors. *Clin Cancer Res.* 2003 Sept.; 9(11): 4132-4138.
14. Tamborini E, Bonadiman L, Greco A, **Gronchi A.**, Riva C, Bertulli R, Casali PG, Pierotti MA and Pilotti S. Alternative expression of ligand-activated kit and PDGFRbeta tyrosine kinase receptors in synovial sarcoma. *Clin Cancer Res* 2004 Feb; 10(3): 938-943.
15. **Gronchi A.**, Diment J, Colecchia M, Fiore M and Santinami M. Atypical pleomorphic epithelioid angiomylipoma localized to the pelvis: a case report and review of the literature. *Histopathology* 2004 Mar; 44(3): 292-295.
16. Rossi CR, Deraco M, De Simone M, Mocellin S, Pilati P, Foletto M, Cavaliere F, Kusamura S, **Gronchi A.**, Lise M. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis. *Cancer* 2004 May 1;100(9):1943-50.
17. **Gronchi A.**, Casali PG, Fiore M, Mariani L, Lo Vullo S, Bertulli R, Colecchia M, Lozza L, Olmi P, Santinami M and Rosai J. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. *Cancer* 2004, 100(11): 2448-2455.
18. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, **Gronchi A.**, Bertulli R, Colecchia M, Casali PG, Pierotti M and Pilotti S. A new mutation in the ATP pocket of Kit receptor is responsible for acquired resistance to Imatinib in a patient with gastrointestinal stromal tumor (GIST). *Gastroenterology* 2004, 127(1):294-9.
19. Ferrari A, **Gronchi A.**, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, Bertulli R, Olmi P, Casali PG. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single

- institution. *Cancer* 2004, 101(3): 627-634.
20. Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, **Gronchi A**, Orlandi R, Ripamonti C, Spreafico C, Alberti D, Bertieri R, Bertulli R, Coco P, Colecchia M, Fumagalli E, Greco A, Grosso F, Negri T, Olmi P, Pierotti MA, Pilotti S. Imatinib mesylate in chordoma. *Cancer* 2004, 101(9):2086-97.
 21. Kusamura S, Raspagliesi F, Baratti D, **Gronchi A**, Casali P, Deraco M. Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: a feasibility study. *J Chemother.* 2004, 16 Suppl 5:19-22.
 22. Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M, Casali PG and **Gronchi A**. Validation and adaptation of a nomogram for predicting survival of extremity soft tissue sarcoma using a three grade system. *Cancer* 2005, 103(2):402-408.
 23. **Gronchi A**, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, Bertulli R, Collini P, Lozza L, Olmi P and Rosai J. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: A series of 911 consecutive patients treated at a single institution. *J Clin Oncol* 2005, 23(1):96-104.
 24. Diment J, Tamborini E, Casali PG, **Gronchi A**, Carney JA and Colecchia M. Carney Triad: case report and molecular analysis of gastric tumor. *Human Path* 2005, 36: 112-116.
 25. Ferrari A, Casanova M, Collini P, Meazza C, Lukcsch R, Massimino M, Cefalo G, Terenziani M, Spreafico F, Catania S, Gandola L, **Gronchi A**, Mariani L and Fossati-Bellani F. Adult-type soft tissue sarcoma in pediatric age: experience at the Istituto Nazionale Tumori in Milan. *J Clin Oncol.* 2005, 23(18): 4021-4030.
 26. Blay JY, Bonvalot S, Casali PG, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, **Gronchi A**, Hogendoorn PCW, Joensuu H, Le Cesne A, Joan Mac Clure, Joan Maurel, Nina Nupponen, Isabelle Ray-Coquard, Peter Reichardt, Raf Sciort, Sigrid Stroobants, Martine van Glabbeke, Allan van Oosterom, Georges D Dimetri. A consensus meeting for the management of gastro-intestinal stromal tumors. Report from the ESMO GIST consensus conference of March 20-21st, 2004. *Ann Oncol.* 2005 Apr;16(4):566-78.
 27. Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, Albertini V, Lagonigro MS, Gabanti E, Caramuta S, Greco A, Torre GD, **Gronchi A**, Pierotti MA, Pilotti S. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. *Cancer.* 2005, 104: 159-169.
 28. Fiore M, Miceli R, Mussi C, Lo Vullo S, Mariani L, Lozza L, Collini P, Olmi P, Casali PG and **Gronchi A**. Dermatofibrosarcoma Protuberans treated at a single institution: a surgical disease with a high cure rate. *J Clin Oncol.* 2005; 23:7669-75.
 29. Casanova M, Ferrari A, Collini P, Bisogno G, Aleggio R, Cecchetto G, **Gronchi A**, Meazza C, Garaventa A, Di Cataldo A, Carli M. Epithelioid Sarcoma in children and adolescents: a report from the Italian soft tissue sarcoma committee. *Cancer.* 2006; 106(3):708-17.
 30. Fiore M, Casali PG, Miceli R, Mariani L, Bertulli R, Lozza L, Collini P, Olmi P, Mussi C and **Gronchi A**. Prognostic effect of re-excision in adult soft tissue sarcoma of the extremities. *Ann Surg Oncol.* 2006; 13(1):110-7.
 31. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S and **Gronchi A**. Malignant peripheral nerve sheath tumours: prognostic factors and survival in a series of patients treated at a single institution. *Cancer.* 2006; 107(5):1065-1074.
 32. Tamborini E, Priol S, Negri T, Lagonigro MS, Miselli F, Greco A, **Gronchi A**, Casali PG, Ferrone M, Fermeiglia M, Carbone A, Pierotti MA, Pilotti S. Functional analyses and molecular modeling of two c-Kit mutations responsible for Imatinib secondary resistance in GIST patients. *Oncogene.* 2006, 25(45): 6140-6146.
 33. Costa A, Daidone MG, Daprao L, Villa R, Cantù S, Pilotti S, Mariani L, **Gronchi A**, Henson JD, Reddel RR and Zaffaroni N. Telomere maintenance mechanisms in liposarcoma: association with histologic subtypes and disease progression. *Cancer Res.* 2006; 66(17):8918-24.
 34. Tamborini E, Miselli F, Negri T, Lagonigro S, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, **Gronchi A**, Perrone F, Carbone A, Pierotti MA, Casali PG and Pilotti S. Molecular and biochemical analyses of PDGFRB, PDGFRA and KIT receptors in chordoma. *Clin Cancer Res.* 2006; 12(23):6920-8.
 35. Pennacchioli E, Deraco M, Mariani L, Fiore M, Mussi C, Collini P, Olmi P, Casali PG, Santinami M and **Gronchi A**. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. *Ann Surg Oncol* 2007; 14(2): 553-9.
 36. **Gronchi A**, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S and Casali PG. Surgery of residual disease following molecular targeted therapy with Imatinib mesylate in advanced/metastatic GIST. *Ann Surg* 2007; 245: 341-346.
 37. Miselli F, Casieri P, Negri T, Orsenigo M, Lagonigro MS, **Gronchi A**, Fiore M, Casali PG, Bertulli R, Carbone A, Pienotti MA, Tamborini E and Pilotti S. c-Kit/PDGFR gene status alterations possibly

- related to primary Imatinib resistance in Gastrointestinal Stromal Tumors. *Clin Cancer Res* 2007; 13(8): 2369-77.
38. Tamborini E, Casieri P, Miselli F, Orsenigo M, Negri T, Piacenza C, Stacchiotti S, **Gronchi A**, Pastorino U, Pierotti MA and Pilotti S. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. *J Pathol* 2007; 212(2):227-235.
 39. **Gronchi A**, Miceli R, Fiore M, Collini P, Lozza L, Grosso F, Mariani L and Casali PG. Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. *Ann Surg Oncol* 2007; 14(5):1583-90.
 40. Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, Collini P, Lozza L, Mariani L, Casali PG and **Gronchi A**. Myxoid/round cell and pleomorphic liposarcoma: prognostic factors and survival in a series of patients treated at a single institution. *Cancer* 109: 2522-2531; 2007.
 41. Casali PG, Stacchiotti S, Sangalli C, Olmi P, **Gronchi A**. Chordoma. *Curr Opin Oncol* 2007; 19(4): 367-370.
 42. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero TC, Jimeno J, D'Incalci M, **Gronchi A**, Fletcher JA, Pilotti S, Casali PG. Efficacy of trabectedin (ET-743) in advanced pre- treated myxoid liposarcomas. *Lancet Oncol* 2007; 8(7): 595-602.
 43. Casanova M, Meazza C, **Gronchi A**, Fiore M, Zaffignani E, Podda M, Collini P, Gandola L, Ferrari A. Soft tissue sarcoma of the extremities in patients of pediatric age. *J Child Orthop* 2007; 1(3):195-203.
 44. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, **Gronchi A**, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J; NCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. *J Natl Compr Canc Netw*. 2007; 5 Suppl 2:S1-29.
 45. **Gronchi A**, Olmi P and Casali PG. Combined modalities approach for localized adult extremity soft tissue sarcoma. *Expert Rev. Anticancer Ther* 2007; 7(8): 1135-1144.
 46. Signoroni S, Frattini M, Negri T, Pastore E, Tamborini E, Casieri P, Orsenigo M, Da Riva L, Radice P, Sala P, **Gronchi A**, Bertario L, Pierotti MA and Pilotti S. Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as potential targets in treating Aggressive Fibromatosis. *Clin Cancer Res* 2007; 13(17): 5034-5040.
 47. Baratti D, Pennacchioli E, Casali PG, Bertulli R, Lozza L, Olmi P, Collini P, Redaelli S, Fiore M and **Gronchi A**. Epithelioid Sarcoma: Prognostic Factors and Survival in a series of Patients Treated at a Single Institution. *Ann Surg Oncol* 2007; 14(12):3542-51.
 48. Ferrari A, Miceli R, Casanova M, **Gronchi A**, Collini P, Meazza C, Zaffignani E, Massimino M, Spreafico F, Mariani L. Adult-type soft tissue sarcomas in paediatric age: A nomogram-based prognostic comparison with adult sarcoma. *Eur J Cancer*. 2007 43(18): 2691-2697.
 49. Venturini L, Erdas R, Costa A, **Gronchi A**, Pilotti S, Zaffaroni N and Daidone MG APB detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcoma. *J Pathol* 2008; 214(4): 410-414.
 50. Fiore M, Locati P, Mussi C, Guarino A, Piva L, Santinami M and **Gronchi A**. Banked venous homograft replacement of the inferior vena cava for primary leiomyosarcoma. *Eur J Surg Oncol* 2008; 34(6): 720-724.
 51. Mussi C, Schildhaus HU, **Gronchi A**, Wardelmann E and Hohenberger P. Therapeutic Consequences From Molecular Biology For GIST Patients Affected By Neurofibromatosis Type 1. *Clin Cancer Res* 2008; 14(14): 4550-4555.
 52. Mussi C, Collini P, Miceli R, Barisella M, Mariani L, Fiore M, Casali PG and **Gronchi A**. Prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of patients surgically treated at a single institution. *Cancer* 2008; 113: 1657-1665.
 53. Miselli F, Negri T, **Gronchi A**, Losa M, Conca E, Brich S, Fumagalli E, Fiore M, Casali PG, Pierotti MA, Tamborini E, Pilotti S. Is autophagy rather than apoptosis the regression driver in Imatinib-treated gastrointestinal stromal tumours ? *Transl Oncol* 2008; 1(4): 177-186.
 54. Negri T, Bozzi F, Conca E, Brich S, **Gronchi A**, Bertulli R, Fumagalli E, Pierotti MA, Tamborini E, Pilotti S. Oncogenic and ligand-dependent activation of KIT/PDGFRα in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). *J Pathol* 2009; 217:103-112
 55. **Gronchi A**, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, Lozza L, Pennacchioli E, Mariani L and Casali PG. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. *J Clin Oncol* 2009; 27(1): 24-30.
 56. Ferrari A, Miceli R, Casanova M, Meazza C, Zaffignani E, **Gronchi A**, Piva L, Collini P, Podda M, Massimino M, Luksch R, Cefalo G, Terenziani M, Spreafico F, Polastri D, Mariani L. Soft Tissue

- Sarcoma of childhood and adolescence: the prognostic role of tumor size changes in relation to the patient's body size. *J Clin Oncol* 2009; 27(3): 371-376..
57. Stacchiotti S, Tamborini E, Marrari A, Brich S, Arisi Rota S, Orsenigo M, Crippa F, Morosi C, **Gronchi A**, Pierotti MA, Casali PG and Pilotti S. Response to sunitinib malate in advanced alveolar soft part sarcoma (ASPS). *Clin Cancer Res* 2009, 15(3): 1096-1104
 58. Pennacchioli E, Fiore M and **Gronchi A**. Hyperthermia as a adjunctive treatment for soft tissue sarcoma. *Expert Rev. Anticancer Ther* 2009, 9(2): 199-210
 59. Forni C, Minuzzo M, Viridis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, **Gronchi A**, Aman P, Casali PG, D'Incalci M, Pilotti S and Mantovani R. Trabectedin (ET-743) promotes differentiation of myxoid liposarcoma tumors. *Mol Cancer Ther* 2009, 8(2): 449-457
 60. **Gronchi A**, Bonvalot S, Le Cesne A and Casali PG. Resection of uninvolved adjacent organs can be part of surgery for retroperitoneal soft tissue sarcoma. *J Clin Oncol* 2009, 27(12):2106-2107
 61. **Gronchi A**, Judson I, Nishida T, Poveda A, Martin J, Reichardt P, Casali PG, Le Cesne A, Hohenberger P, Blay JY. Adjuvant treatment with Imatinib for GIST: solid ground or still quicksand ? A comment on behalf of the EORTC soft tissue and bone sarcoma group, the Italian sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group, the Spanish Sarcoma Group (GEIS). *Eur J Cancer* 2009, 45(7):1103-1106.
 62. Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, Piovesan C, Dileo P, Torri V, **Gronchi A** and Casali PG Tumor response assessment in high grade soft tissue sarcomas (STS): a pilot study to assess the correlation between radiological and pathological response using both RECIST and Choi's criteria. *Radiology* 2009, 251(2): 447-456
 63. Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG and **Gronchi A**. Preoperative Imatinib mesylate for unresectable or locally advanced primary Gastrointestinal Stromal Tumors (GIST). *Eur J Surg Oncol* 2009, 35: 739-745.
 64. Thomas DM, O'Sullivan B and **Gronchi A**. Current concepts and future perspectives in Retroperitoneal Soft Tissue Sarcoma management. *Expert Rev Anticancer Ther* 2009, 9(8):1145-57
 65. Reichardt P, Hogendoorn PC, Tamborini E, Loda M, **Gronchi A**, Poveda A, Schöffski P. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. *Semin Oncol.* 2009, 36(4):290-301.
 66. Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Péchoux C, Casali PG, Le Cesne A, **Gronchi A** and Bonvalot S. Desmoid-Type Fibromatosis: a front-line conservative approach to select patients for surgical treatment. *Ann Surg Oncol* 2009, 16(9): 2587-2593.
 67. Grosso F, Sanfilippo R, Viridis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J, D'Incalci M, **Gronchi A**, Pilotti S and Casali PG. Trabectedin in Myxoid Liposarcomas (MLS): a long-term analysis of a single institution series. *Ann Oncol* 2009, 20(8):1439-44
 68. Colombo C and **Gronchi A**. Desmoid-type fibromatosis: what works best? *Eur J Cancer* 2009, 45 suppl1: 466-467.
 69. Conca E, Negri T, **Gronchi A**, Fumagalli E, Tamborini E, Pavan GM, Fermeglia M, Pierotti MA, Priol S and Pilotti S. Activate and Resist: L576P in GIST. *Mol Cancer Ther* 2009, 8(9):2491-2495
 70. Stacchiotti S, Marrari A, Tamborini E, Palassini E, Viridis E, Messina A, Crippa F, Morosi C, **Gronchi A**, Pilotti S and Casali PG. Response to imatinib plus sirolimus in advanced chordoma. *Ann Oncol* 2009; 20(11):1886-1894.
 71. Perrone F, Da Riva L, Orsenigo M, Losa M, Jocolle G, Millefanti C, Pastore E, **Gronchi A**, Pierotti MA, and Pilotti S. PDGFRA, PDGFRB, EGFR and downstream signalling activation in malignant peripheral nerve sheath tumour. *Neuro Oncology* 2009; 11(6): 725-736
 72. Stacchiotti S, Casali PG, Lo Vullo S, Mariani L, Palassini E, Mercuri M, Alberghini M, Pilotti S, Zanella L, **Gronchi A** and Picci P. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centres. *Ann Surg Oncol* 2010; 17: 211-219
 73. Meazza C, Bisogno G, **Gronchi A**, Fiore M, Cecchetto G, Alaggio R, Milano GM, Casanova M, Carli M, Ferrari A. Aggressive fibromatosis in children and adolescents: the italian experience. *Cancer* 2010; 116(1):233-240
 74. Mussi C, Ronellenfisch U, Jakob J, Tamborini E, Reichardt P, Casali PG, Fiore M, Hohenberger P and **Gronchi A**. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients ? *Ann Oncol* 2010; 21(2):403-408
 75. **Gronchi A**, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, Fiore M and Casali PG. Extremity soft tissue sarcoma in a series of patients treated at a single institution: the local control directly impacts survival. *Ann Surg* 2010; 251: 512-517
 76. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, **Gronchi A**, Viridis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M and Allavena P. Anti-tumor and anti-inflammatory effects of

- Trabectedin on human myxoid liposarcoma cells. *Cancer Res* 2010; 70(6): 2235-2244
77. **Gronchi A**, Blay JY and Trent JC. The Role of High-Dose Imatinib in the Management of Patients with Gastrointestinal Stromal Tumor (GIST). *Cancer* 2010; 116(8):1847-1858
 78. Stacchiotti S, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, **Gronchi A** and Casali PG. Tumor response to Sunitinib Malate observed in Clear Cell Sarcoma. *Ann Oncol* 2010; 21(5):1130-1131
 79. Ardoino I., Miceli R, Berselli M, Mariani L, Biganzoli E, Fiore M, Collini P, Stacchiotti S, Casali PG and **Gronchi A**. Histology-Specific Nomogram for Primary Retroperitoneal Sarcoma. *Cancer* 2010; 116: 2429-2436
 80. Stacchiotti S, Negri T, Palassini E, Conca E, **Gronchi A**, Morosi C, Messina A, Pastorino U, Pierotti MA, Casali PG and Pilotti S. Sunitinib malate and Figitumumab in solitary fibrous tumor (SFT): patterns and molecular bases of tumor response. *Mol Cancer Ther* 2010; 9(5): 1286-1297
 81. Bonvalot S, Miceli R, Berselli M, Causeret S, Colombo C, Mariani L, Bouzaiene H, Le Pechouz C, Casali PG, Le Cesne A, Fiore M and **Gronchi A**. Aggressive Surgery in Retroperitoneal Soft Tissue Sarcoma carried out at high volume centers is safe and associated to an improved local control. *Ann Surg Oncol* 2010; 17: 1507-1514
 82. Venturini L, Motta R, **Gronchi A**, Daidone MG and Zaffaroni N. Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. *BMC Cancer* 2010; 10: 254
 83. Tamborini E, Viridis E, Negri T, Orsenigo M, Brich S, Conca E, **Gronchi A**, Stacchiotti S, Manenti G, Casali PG, Pierotti MA and Pilotti S. Analysis of Receptor Tyrosine Kinases (RTK) and Downstream Pathways in Chordomas. *Neuro Oncol* 2010; 12(8): 776-789
 84. Frapolli R, Tamborini E, Viridis E, Bello E, Tarantino E, Marchini S, Grosso F, Sanfilippo R, **Gronchi A**, Tercero J, Peloso G, Casali PG, Pilotti S, D'Incalci M. Novel models of Myxoid Liposarcoma Xenografts mimicking the biological and pharmacological features of human tumors. *Clin Cancer Res* 2010;16(20):4958-4967
 85. Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, Stacchiotti S, Casali PG and **Gronchi A**. Alveolar Soft Part Sarcoma: clinical presentation, treatment and outcome in a series of 33 patients at a single institution. *Ann Surg Oncol* 2010; 17: 3229-3233
 86. Baratti D, Pennacchioli E, Kusamura S, Fiore M, Balestra MR, Colombo C, Mingrone E, **Gronchi A** and Deraco M. Peritoneal Sarcomatosis: is there a subset of patients who may benefit of a cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? *Ann Surg Oncol* 2010; 17(12): 3220-3228
 87. Orsenigo M, Brich S, Riva C, Conca E, Bertulli R, Dileo P, **Gronchi A**, Casali PG, Pierotti MA, Tamborini E, Pilotti S. Fluorescence in situ hybridization analysis and immunophenotyping of c-kit/PDGFRα and Bcl-2 expression in gastrointestinal stromal tumors. *Anal Quant Cytol Histol* 2010; 32(4): 225-233
 88. Gennaro M, Valeri B, Casalini P, Carcangiu ML, **Gronchi A**, Conti AR, Agresti R, Greco M. Angiosarcoma of the breast and vascular endothelial growth factor receptor. *Tumori*. 2010; 96(6):930-935.
 89. Dileo P, Priol S, Tamborini E, Negri T, Stacchiotti S, **Gronchi A**, Posocco P, Laurini E, Coco P, Fumagalli E, Casali PG, Pilotti S. Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRα mutations: an imaging, biochemical and molecular modeling study. *Int J Cancer* 2011; 128(4): 983-990
 90. Gasparini P, Facchinetti F, Boeri M, Lorenzetto E, Livio A, **Gronchi A**, Ferrari A, Massimino M, Spreafico F, Giangaspero F, Forni M, Maestro R, Alaggio R, Pilotti S, Collini P, Modena P and Sozzi G. Prognostic determinants in Epithelioid Sarcoma. *Eur J Cancer* 2011; 47: 287-295
 91. Bonvalot S and **Gronchi A**. ILP and RT: the study that will never be. *Ann Surg Oncol* 2011; 18: 303-305
 92. Sanfilippo R, Miceli R, Grosso F, Fiore M, Pennacchioli E, Puma E, Barisella M, Sangalli C, Mariani L, Casali PG and **Gronchi A**. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. *Ann Surg Oncol* 2011; 18: 720-725
 93. **Gronchi A**, Miceli R, Colombo C, Collini P, Stacchiotti S, Olmi P, Mariani L, Bertulli R, Fiore M and Casali PG. Primary Extremity Soft Tissue Sarcoma: outcome improvement over time at a single institution. *Ann Oncol* 2011; 22(7): 1675-1681
 94. Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, Conca E, Bozzi F, Cassinelli G, **Gronchi A**, Casali PG and Pilotti S. Sunitinib in advanced alveolar soft part sarcoma: evidence of direct antitumor effect. *Ann Oncol* 2011; 22(7): 1682-1690
 95. Bozzi F, Conca E, Manenti G, Negri T, Brich S, **Gronchi A**, Pierotti MA, Tamborini E, Pilotti S. High CD133 expression levels in gastrointestinal stromal tumors. *Cytometry B Clin Cytom* 2011; 80(B): 238-247
 96. **Gronchi A** and Pollock RE. Surgery in retroperitoneal soft tissue sarcoma: a call for a consensus between Europe and North America. *Ann Surg Oncol* 2011; 18: 2107-2110
 97. Stacchiotti S, Pedetour F, Negri T, Conca E, Marrari A, Palassini E, Collini P, Keslair F, Morosi C, **Gronchi A**, Pilotti S and Casali PG. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical

- history, biological profile and sensitivity to imatinib. *Int J Cancer* 2011; 129(7): 1761-1772
98. Rossi S, Miceli R, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Toffolatti L, Laurino L, Mariani L, Vinaccia V, Gnocchi C, **Gronchi A**, Casali PG and Dei Tos AP. Natural history of Imatinib-naïve GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. *Am J Surg Pathol* 2011; 35(11):1646-1656
 99. Da Riva L, Bozzi F, Mondellini P, Micciché F, Fumagalli E, Vaghi E, Tarantino E, Huber V, **Gronchi A**, Tamborini E, Pierotti MA, Pilotti S and Bongarzone I. Proteomic detection of a large amount of SCGF α in the stroma of GISTs after imatinib therapy. *J Transl Med* 2011; 9:158
 100. Negri T, Brich S, Conca E, Bozzi F, Orsenigo M, Stacchiotti S, Alberghini M, Mauro V, **Gronchi A**, Dusio GF, Pelosi G, Picci P, Casali PG, Pierotti MA, Pilotti S. Receptor Tyrosine Kinase Pathway Analysis Sheds Light on Similarities between Clear Cell Sarcoma and Metastatic Melanoma. *Gene Chromosomes Cancer* 2012; 51(2): 111-126
 101. Fiore M, Colombo C, Locati P, Berselli M, Radaelli S, Morosi C, Casali PG and **Gronchi A**. Surgical technique, morbidity and outcome of primary retroperitoneal sarcoma involving inferior vena cava. *Ann Surg Oncol* 2012; 19(2): 511-518.
 102. **Gronchi A**, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, Hohl RJ, Demetri GD, Le Cesne A, Lardelli P, Perez I, Nieto A, Tercero JC, Alfaro V, Tamborini E and Blay JY. Phase II Clinical Trial of Neoadjuvant Trabectedine in patients with advanced localized myxoid liposarcoma. *Ann Oncol* 2012; 23(3): 771-776
 103. **Gronchi A**, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG and Picci P. Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas (STS): a Randomized Clinical Trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS). *J Clin Oncol* 2012; 30(8): 350-356
 104. Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, Spreafico C, **Gronchi A**, Amore P, Vinaccia V and Casali PG. A Phase II study on imatinib in advanced chordoma. *J Clin Oncol* 2012; 30(9): 914-920
 105. **Gronchi A** and Raut CP. The combination of Surgery and Imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. *Ann Surg Oncol* 2012; 19: 1051-1055
 106. **Gronchi A**, Miceli R, Colombo C, Stacchiotti S, Collini P, Mariani L, Sangalli C, Radaelli S, Sanfilippo R, Fiore M and Casali PG. Frontline extended surgery is associated with improved survival in retroperitoneal low-intermediate grade soft tissue sarcomas. *Ann Oncol* 2012; 23(4):1067-1073
 107. Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, **Gronchi A**, Corless CL, Goldstein D, Rubin B, Maki RB, Lazar AJ, Lev D, Trent JC and von Mehren M. Non-random association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): Case series of 28 patients. *Ann Oncol* 2012; 23(5): 1335-1340
 108. Venturini L, Daidone MG, Motta R, Hoare SF, **Gronchi A**, Folini M, Keith WN, Zaffaroni N. Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. *Neuro-oncology* 2012;14(6):736-744.
 109. Collini P, Negri T, Barisella M, Stacchiotti S, Palassini E, Tarantino E, Pastorino U, **Gronchi A**, Casali PG and Pilotti S High-Grade sarcomatous overgrowth in Solitary Fibrous Tumors: a clinical-pathological study of 10 cases. *Am J Surg Pathol* 2012; 36(8):1202-1215
 110. Casali PG, Fumagalli E and **Gronchi A**. Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST). *Curr Treat Opt in Oncol* 2012; 13(3):277-284
 111. Bonvalot S, Raut CP, Pollock RE, Rutkowski P, Strauss DC, Hayes AJ, Van Coevorden F, Fiore M, Stoeckle E, Hohenberger P and **Gronchi A**. Technical Considerations in Surgery For Retroperitoneal Sarcomas. Position paper from e-SURGE, a masterclass in sarcoma surgery, and EORTC - STBSG. *Ann Surg Oncol* 2012; 19(9):2981-2991
 112. Colombo C, Ronellenfitsch U, Yuxin Z, Rutkowski P, Miceli R, Bylina E, Hohenberger P, Raut CP and **Gronchi A**. Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center study. *Ann Surg Oncol* 2012; 19(11):3361-3367
 113. Reichardt P, Morosi C, Wardelmann E and **Gronchi A**. Gastrointestinal stromal tumors: Evolving role of the multidisciplinary team approach in management. *Expert Rev Anticancer Ther* 2012; 12(8):1053-1068
 114. Colombo C, Randall L, Andtbacka RHI and **Gronchi A**. A new surgical perspective in soft tissue sarcoma (STS) management: more conservative in ESTS (Extremity Soft Tissue Sarcoma), more extended in RSTS (Retroperitoneal Soft Tissue Sarcoma). *Expert Rev Anticancer Ther* 2012; 12(8):1079-1087
 115. Colombo C, Miceli R, Collini P, Radaelli S, Palassini E, Stacchiotti S, Fiore M, Mariani L, Casali PG and **Gronchi A**. Leiomyosarcoma and sarcoma with myogenic differentiation: two different entities

- or two faces of the same disease? *Cancer* 2012; 118(21): 5349-5357
116. Stacchiotti S, Dagrada P, Morosi C, Negri T, Romanini A, Pilotti S, **Gronchi A** and Casali PG. Extraskeletal Myxoid Chondrosarcoma: tumor response to Sunitinib. *Clin Sarcoma Res* 2012; 2(1): 22
 117. Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P, Llombart-Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Casali PG and **Gronchi A**. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy: an exploratory analysis on a Phase III trial. *Cancer* 2012; 118(23):5857-5866
 118. Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, **Gronchi A**, Dei Tos AP, Morosi C, Messina A, Pilotti S, Casali PG. Sunitinib malate in solitary fibrous tumor (SFT). *Ann Oncol* 2012; 23(12):3171-3179
 119. **Gronchi A** and Raut CP. Optimal approach to sporadic desmoid tumor: from radical surgery to observation. Time for a consensus ? *Ann Surg Oncol* 2012; 19:3995-3997
 120. Jakob J, Mussi C, Ronellenfitsch U, Wardelmann E, Negri T, **Gronchi A** and Hohenberger P. Gastrointestinal Stromal Tumor (GIST) of the rectum: results of surgical and multimodality therapy in the era of Imatinib. *Ann Surg Oncol* 2013; 20(2):586-592.
 121. **Gronchi A**. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with GIST. *Eur J Cancer* 2013; 49: 884-892
 122. **Gronchi A**, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Palassini E, Stacchiotti S, Ferrari S, Fiore M and Casali PG. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. *Ann Oncol* 2013; 24(3):817-23
 123. **Gronchi A**, Miceli R, Shurell E, Eilber FC, Eilber FR, Anaya DA, Kattan MW, Honoré C, Lev DC, Colombo C, Bonvalot S, Mariani L and Pollock RE. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center datasets. *J Clin Oncol* 2013; 31:1649-1655
 124. Stacchiotti S, Libertini M, Negri T, Palassini E, **Gronchi A**, Fatigoni S, Poletti P, Vincenzi B, Dei Tos AP, Mariani L, Pilotti S and Casali PG. Response to chemotherapy of Solitary Fibrous Tumor: a retrospective study. *Eur J Cancer* 2013; 49(10): 2376-2383
 125. **Gronchi A** and Pollock RE. Quality of local treatment or biology of the tumor: which are the trump cards for loco-regional control of retroperitoneal sarcoma? *Ann Surg Oncol* 2013; 20: 2111-2113.
 126. Stacchiotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, Morosi C, Casale A, Crippa F, Conca E, Negri T, Palassini E, Marrari A, Palmerini E, Mariani L, **Gronchi A**, Pilotti S, Casali PG. Phase II Study on Lapatinib in advanced EGFR positive Chordoma. *Ann Oncol* 2013; 24: 1931-1936
 127. Rutkowski P and **Gronchi A**. Efficacy and economic value of adjuvant Imatinib in GIST. *The Oncologist* 2013; 18: 689-696.
 128. Duranti L, **Gronchi A**, Stacchiotti S, Fiore M, Casali PG, Collini P, Pelosi G, Galeone C and Pastorino U. Localized thoracic sarcomas: outcome improvement over time at a single institution. *Eur J Cancer* 2013; 49: 2689-2697
 129. Baldi G, Stacchiotti S, Mauro V, Dei Tos AP, **Gronchi A**, Pastorino U, Duranti L, Provenzano S, Marrari A, Libertini M, Pilotti S and Casali PG. Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. *Clin Sarcoma Res* 2013; 3(1): 4
 130. Stacchiotti S, Crippa F, Messina A, Pilotti S, **Gronchi A**, Blay JY and Casali PG. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. *Clin Sarcoma Res* 2013; 3(1): 8
 131. Mattavelli D, Miceli R, Radaelli S, Mattavelli F, Cantù G, Barisella M, Quattrone P, Stacchiotti S, Sangalli C, Casali PG, **Gronchi A** and Fiore M. Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. *Ann Oncol* 2013; 24(8): 2181-2189
 132. Rutkowski P, **Gronchi A**, Hohenberger P, Bonvalot S, Schöffski P, Bauer S, Fumagalli E, Nyckowski P, Nguyen BP, Kerst JM, Fiore M, Bylina I, Hoiczky M, Cats A, Casali PG, Le Cesne A, Treckmann J, Stoeckle E, van de Wilt JH, Sleijfer S, Tielen R, van der Graaf W, Verhoef C and van Coevorden F. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST), the EORTC STBSG experience. *Ann Surg Oncol* 2013; 20(9): 2937-2943
 133. **Gronchi A** and Casali PG. Adjuvant Therapy for High-Risk Soft Tissue Sarcoma in the Adult. *Curr Treat Opt in Oncol* 2013; 14(3):415-24
 134. Stacchiotti S, Tortoreto M, Bozzi F, Tamborini E, Morosi C, Messina A, Libertini M, Palassini E, Cominetti D, Negri T, **Gronchi A**, Pilotti S, Zaffaroni N and Casali PG. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-à-vis temozolomide and antiangiogenics. *Clin Cancer Res* 2013; 19(18):5192-201
 135. **Gronchi A**. Extended surgery for retroperitoneal sarcoma: the key to maximizing the potential for cure and survival. *Pro. Oncology (Williston Park)*. 2013; 27(7):640, 642
 136. **Gronchi A** and Raut CP. Treatment of localized sarcomas. *Hematol Oncol Clin N Am* 2013; 27:921-

137. Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Le Cesne A, Hartgrink HH, Cleton-Jansen AM, Domont J, Bovée JVMG, Bonvalot S, Lev D, and **Gronchi A**. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent multicenter validation study. *Cancer* 2013; 119:3696-3702.
138. Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocollé J, Sanfilippo R, **Gronchi A**, Perrone F, Tamborini E, Pelosi G, Pierotti M, Maestro R, Pricl S and Pilotti S. In vitro and in silico studies of MDM2/MDMX isoforms predict NUTLIN-3A sensitivity in well/de-differentiated liposarcomas. *Lab Invest* 2013; 93(11): 1232-1240
139. Bonvalot S, Ternès N, Fiore M, Bitsakou G, Colombo C, Honoré C, Marrari A, Le Cesne A, Perrone F, Dunant A and **Gronchi A**. Spontaneous regression of primary abdominal wall desmoids: more common than previously thought. *Ann Surg Oncol* 2013; 20(13): 4096-4102
140. Raut CP and **Gronchi A**. Cytoreductive Surgery in Advanced GIST: timing is everything. *Ann Surg Oncol* 2013; 20(13): 4059-4060
141. Stacchiotti S, Dagrada G, Sanfilippo R, Negri T, Vittimberga I, Ferrari S, Grosso F, Apice G, Tricomi M, Colombo C, **Gronchi A**, Dei Tos AP, Pilotti S and Casali PG. Anthracycline-based CT in extraskeletal myxoid chondrosarcoma: a retrospective study. *Clinical Sarcoma Research* 2013; 3: 16.
142. Martin-Broto J, Gutierrez AM, Ramos RF, Lopez-Guerrero JA, Ferrari S, Stacchiotti S, Picci P, Calabuig S, Collini P, Gambarotti M, Bague S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martinez-Trufero J, Poveda A, Casali PG, Fernandez A, Lopez-Pousa A and **Gronchi A**. MRP1 overexpression determines poor prognosis in prospectively treated localized high risk soft tissue sarcoma patients of limbs and trunk wall. An ISG/GEIS study. *Mol Cancer Ther* 2014, 13(1):249-59
143. Bozzi F, Manenti G, Conca E, Stacchiotti S, Messina A, Dagrada G, **Gronchi A**, Panizza P, Pierotti M, Tamborini E and Pilotti S. Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies. *Neuro-Oncol* 2014; 16(1):72-80
144. **Gronchi A**, De Paoli A, Dani C, Merlo DF, Quagliuolo V, Grignani G, Bertola G, Navarria P, Sangalli C, Buonadonna A, De Sanctis R, Sanfilippo R, Dei Tos AP, Stacchiotti S, Giorello L, Fiore M, Bruzzi P and Casali PG. Preoperative chemo-radiation therapy for localized retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. *Eur J Cancer* 2014; 50:784-792
145. **Gronchi A**, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M and Bonvalot S on behalf of ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm. A position paper from the Italian and the French Sarcoma Group. *Ann Oncol* 2014; 25(3): 578-583
146. Meazza C, Luksch R, Daolio P, Podda M, Luzzati A, **Gronchi A**, Parafioriti A, Gandola L, Collini P, Ferrari A, Casanova M, Terenziani M, Spreafico F, Polastri D, Biondi V, Schiavella E, Pecori E, Massimino M. Axial Skeletal Osteosarcoma: a 25 year monoinstitutional experience in children and adolescence. *Med Onc* 2014; 31(4): 875
147. Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczky M, Cats A, Casali PG, Treckmann J, van Coevorden F, **Gronchi A**. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - analysis of prognostic factors (EORTC-STBSG collaborative study). *Eur J Surg Oncol* 2014; 40(4):412-419
148. Pastorino U, Duranti L, Scannagatta P, Leo F, Piccioni F, Collini P and **Gronchi A**. Thoracopneumonectomy with rib-like reconstruction for recurrent thoracic sarcomas. *Ann Surg Oncol* 2014; 21(5):1610-1615
149. Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, Le Cesne A, Gladdy RA, Casali PG, Swallow CJ, **Gronchi A**, Bonvalot S and Raut RP. Desmoid-type Fibromatosis and pregnancy. A multi-institutional analysis of recurrence and obstetric risk. *Ann Surg* 2014; 259(5):973-978.
150. Radaelli S, Stacchiotti S, Casali PG and **Gronchi A**. Emerging Therapies for Adult Soft Tissue Sarcomas. *Exp Rev Anticancer Ther* 2014; 14(6):689-704
151. Stacchiotti S, Pantaleo MA, Astolfi A, Dagrada GP, Negri T, Dei Tos AP, Indio V, Morosi C, **Gronchi A**, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestri R, Pilotti S and Casali PG. Activity of Sunitinib in Extraskeletal Myxoid Chondrosarcoma. *Eur J Cancer* 2014; 50(9): 1657-1664
152. **Gronchi A**, Colombo C and Raut CP. Surgical Management of Localized Soft Tissue Tumors. *Cancer* 2014; 120(17):2638-2648
153. De Cecco L, Negri T, Brich S, Mauro V, Bozzi F, Dagrada GP, Disciglio V, Sanfilippo R, **Gronchi A**, D'Incalci M, Casali PG, Canevari S, Pierotti MA, Pilotti S. Identification of a gene expression driven progression pathway in Myxoid Liposarcoma. *Oncotarget* 2014; 5(15):5965-5977
154. Radaelli S, Desai A, Hodson J, Colombo C, Roberts K, Gourevitch D and **Gronchi A**. Prognostic factors and outcome of Spermatic Cord Sarcoma. *Ann Surg Oncol* 2014; 21:3557-3563
155. Di Giandomenico S, Frapolli R, Bello E, Ubaldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro

- V, Tamborini E, Pilotti S, Casali PG, Grosso F, Sanfilippo R, **Gronchi A**, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JMF and D'Incalci M. Mode of action of trabectedin in myxoid liposarcoma. *Oncogene* 2014; 33(44):5201-5210
156. Tazzari M, Negri T, Rini F, Vergani B, Huber V, Villa A, Dagrada P, Colombo C, Fiore M, **Gronchi A**, Stacchiotti S, Casali PG, Pilotti S, Rivoltini L and Castelli C. Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. *Br J Cancer* 2014; 11(7):1350-1362
 157. van Broekhoven DLM, Deroose JP, Bonvalot S, **Gronchi A**, Grünhagen DJ, Eggermont AMM and Verhoef C. Isolated limb perfusion by tumor necrosis factor alpha and melphalan in patients with advanced aggressive fibromatosis. *Br J Surg* 2014; 101(13):1674-80.
 158. Le Cesne A, Ouali M, Leahy MG, Santoro, Hoekstra HJ, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward WP, **Gronchi A**, Hogendoorn PCW, Litiere S, Marreaud S, Blay JY and Van Der Graaf WTA. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. *Ann Oncol* 2014; 25(12):2425-2432
 159. Sanfilippo R, Bertulli R, Marrari A, Fumagalli E, Pilotti S, Morosi C, Messina A, Dei Tos AP, **Gronchi A** and Casali PG. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. *Clin Sarcoma Res* 2014; 4:16
 160. Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, **Gronchi A**, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG and Zaffaroni N. Preclinical and clinical evidence of activity of Pazopanib in Solitary Fibrous Tumor. *Eur J Cancer* 2014; 50(17):3021-8
 161. Morosi C, Stacchiotti S, Marchianò A, Bianchi A, Radaelli S, Sanfilippo R, Colombo C, Richardson C, Collini P, Barisella M, Casali PG, **Gronchi A**, Fiore M. Correlation between Radiological Assessment and Histopathological Diagnosis in Retroperitoneal Tumors: analysis of 291 consecutive patients at a tertiary referral Sarcoma Center. *Eur J Surg Oncol* 2014; 40(12):1662-1670
 162. Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult. A Consensus Approach from the Trans-Atlantic RPS Working group* *Ann Surg Oncol* 2015; 22(1): 256-263
 163. Kasper B, Baumgarten C, Bonvalot S, Haas R, Haller F, Hohenberger P, Moreau G, Van der Graaf W and **Gronchi A**. Management of Sporadic Desmoid-Type Fibromatosis: A European consensus approach based on patients' and professionals' expertise - A Sarcoma Patients EURONET (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC) / Soft Tissue and Bone Sarcoma Group (STBSG) initiative. *Eur J Cancer* 2015; 51(2):127-136
 164. Colombo C, Miceli R, Le Péchoux C, Palassini E., Honoré C, Stacchiotti S, Mir O , Casali PG, Dômont J, Fiore M, Le Cesne A, **Gronchi A** and Bonvalot S. Sporadic Extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. *Eur J Cancer* 2015; 51(2):186-192
 165. Palmerini E, Staals EL, Maki RG, Pengo S, Cioffi A, Gambarotti A, Picci P, Daolio PA, Parafioriti A, Morris C, Antonescu CR, **Gronchi A**, Casali PG, Donati DM, Ferrari S, Stacchiotti S. Tenosynovial giant cell tumor/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. *Eur J Cancer* 2015; 51(2):210-217
 166. **Gronchi A**. Individualizing the use/non-use of radiation therapy (RT) in soft tissue sarcoma (STS): when abstention is better than care. *J Surg Oncol* 2015; 111(2):133-134
 167. **Gronchi A**, Collini P, Miceli R, Renne SL, Dagrada G, Fiore M, Sanfilippo R, Barisella M, Colombo C, Morosi C, Stacchiotti S, Casali PG, Dei Tos AP and Pilotti S. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma. *Am J Surg Pathol* 2015; 39(3):383-93
 168. Colombo C, Baratti D, Kusamura S, Deraco M and **Gronchi A**. The role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Isolated Perfusion (ILP) Interventions in Sarcoma. *J Surg Oncol* 2015; 111(5):570-579
 169. Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA, Casanova J, Esler C, Ferrari S, Funovics PT, Gerrand C, Grimer R, **Gronchi A**, Haffner N, Hecker-Nolting S, Höller S, Jeys L, Jutte P, Leithner A, San-Julian M, Thorkildsen J, Vincenzi B, Windhager R, Whelan J. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study.. *Eur J Cancer* 2015; 51(3):374-81.
 170. **Gronchi A**, Miceli R, Allard MA, Callegaro D, Le Péchoux C, Fiore M, Honoré C, Sanfilippo R, Coppola S, Stacchiotti S, Terrier P, Casali PG, Le Cesne A, Mariani L, Colombo C and Bonvalot S. Personalizing the approach to Retroperitoneal Soft Tissue Sarcoma: histology specific patterns of failure and post-relapse outcome after primary extended resection. *Ann Surg Oncol* 2015; 22(5):1447-54
 171. Bellera CA, Penel M, Bonvalot S, Casali PG, Nielsen OS, Delannes M, Litiere S, Bonnetain F, Dabakuyo TS, Benjamin R, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grossclaude P, **Gronchi A**, Haas R, Hohenberger P, Issels R,

- Italiano A, Jooste V, Karup-Hansen A, Le Pechoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut CP, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van Glabbeke M, Woll P, Gorgou-Bourgade S, Mathoulin-Pelissier S. Guidelines for time-to-event endpoint definitions in sarcoma and gastrointestinal stromal tumor (GIST) trials. Results of the DATECAN initiative (Definition for the Assessment of Time-to event Endpoints in CANcer trials). *Ann Oncol* 2015; 26:865-872
172. Callegaro D, Fiore M and **Gronchi A**. Personalizing surgical margins in retroperitoneal sarcoma. *Exp Rev Anticancer Ther* 2015; 15(5):553-67
 173. Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, Marzotto A, Boscato E, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Mariani L, Amore P, **Gronchi A**, Casali PG, Maestro R, and Dei Tos AP. KIT, PDGFRA and BRAF mutational spectrum impacts on the natural history of Imatinib-naïve localized GIST: a population-based study. *Am J Surg Pathol* 2015; 39(7):922-930
 174. Callegaro D, Miceli R, Brunelli C, Colombo C, Sanfilippo R, Radaelli S, Casali PG, Caraceni A, **Gronchi A**, Fiore M. Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. *Br J Surg* 2015; 102:1079-1087
 175. Dagrada GP, Spagnuolo RD, Mauro V, Tamborini E, Cesana L, **Gronchi A**, Stacchiotti S, Pierotti MA, Negri T and Pilotti S. Solitary Fibrous Tumor: loss of chimeric protein expression and genomic instability mark dedifferentiation. *Mod Pathol* 2015; 28(8):1074-1083
 176. Hohenberger P, Gorlick R, **Gronchi A**. Collaborations Between SSO and the Connective Tissue Oncology Society (CTOS) Series. *Ann Surg Oncol* 2015; 22(9): 2815-2816
 177. Palassini E, Ferrari S, Verderio P, De Paoli A, Martin Broto J, Quagliuolo V, Comandone A, Sangalli C, Palmerini E, Lopez-Pousa A, De Sanctis R, Bottelli S, Libertini M, Picci P, Casali PG and **Gronchi A**. Feasibility of pre-operative chemotherapy + radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk within the ISG/GEIS randomized clinical trial on 3 vs 5 cycles of full-dose epirubicin + ifosfamide. *J Clin Oncol* 2015; 33(31):3628-3634
 178. Hindi N, Casali PG, Morosi C, Messina A, Palassini E, Pilotti S, Tamborini E, Radaelli S, **Gronchi A**, Stacchiotti S. Imatinib in advanced chordoma: a retrospective case series analysis. *Eur J Cancer* 2015; 51:2609-14
 179. Fiore M, Colombo C, Radaelli S, Callegaro D, Palassini E, Barisella M, Morosi C, Baldi GG, Stacchiotti S, Casali PG, **Gronchi A**. Hormonal manipulation with Toremifene in Sporadic Desmoid-type Fibromatosis. *Eur J Cancer* 2015; 51:2800-2807
 180. Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann J, Goldstein D, Martin Broto J, **Gronchi A**, Dei Tos AP, Matreud S, van der Graaf W, Zalcberg JR, Litiere S and Blay JY. Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with Imatinib as an adjuvant: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS). *J Clin Oncol* 2015; 33:4276-4283
 181. Wardelmann E, Haas RL, Bovée JVMG, Terrier Ph, Lazar A, Messiou C, LePechoux C, Hartmann W, Collin F, Fisher C, Mechttersheimer G, Dei Tos AP, Stacchiotti S, Jones R, **Gronchi A**, Bonvalot S. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. *Eur J Cancer* 2016; 53:84-95
 182. Messiou C, Bonvalot S, **Gronchi A**, Vanel D, Meyer M, Robinson P, Morosi C, Bloem JL, Terrier PH, Lazar A, LePechoux C, Wardelman E, Winfield JM, Boulet B, Haas RL. Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on Magnetic Resonance Imaging. *Eur J Cancer* 2016; 56: 37-44
 183. Stacchiotti S, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, Urbini M, Indio V, Maestro R, **Gronchi A**, Fiore M, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, Casali PG. Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP). *Clin Cancer Res* 2016; 22(4):837-46
 184. Vlenterie M, Litière S, Rizzo E, Marréaud S, Judson I, Gelderblom I, Le Cesne A, Wardelmann E, Messiou C, **Gronchi A**, van der Graaf WTA. Outcome of chemotherapy in advanced synovial sarcoma patients: review of 15 clinical trials from European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG); Setting a new landmark for studies in this subtype. *Eur J Cancer* 2016; 58: 62-72
 185. **Gronchi A**, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski

- P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, Casali PG, Pollock RE and Raut CP. Variability in patterns of recurrence after resection of Primary Retroperitoneal Sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative Transatlantic RPS Working Group. *Ann Surg* 2016; 263(5):1002-1009
186. Raut CP, Miceli R, Strauss DC, Swallow CJ, Hohenberger P, van Coevorden F, Rutkowski P, Fiore M, Callegaro D, Casali PG, Haas RL, Hayes AJ, Honoré C, Cannell AJ, Jakob J, Szacht M, Fairweather M, Pollock RE, Bonvalot S, **Gronchi A**. External Validation of a Multi-Institutional Retroperitoneal Sarcoma Nomogram. *Cancer* 2016; 122(9):1417-24
 187. Bogani G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Lorusso D, Sabatucci I, Carcangiu ML, Fiore M, **Gronchi A**, Raspagliesi F. Morcellator's port-site metastasis of a uterine smooth muscle tumor of uncertain potential after minimally invasive myomectomy. *J Minim Invasive Gynecol.* 2016; 23(4):647-9.
 188. Saponara M, Stacchiotti S and **Gronchi A**. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. *Exp Rev Anticancer Ther* 2016; 16(5):473-484
 189. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Le Pechoux C, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Mariani L, Wunder JS, Pollock RE, Casali PG and **Gronchi A**. Development and external validation of two nomograms to predict overall survival and distant metastases after surgical resection of localised soft tissue sarcomas of the extremities: a retrospective analysis. *Lancet Oncol* 2016; 17:671-680
 190. Radaelli S, Fiore M, Colombo C, Ford S, Palassini E, Sanfilippo R, Stacchiotti S, Sangalli C, Morosi C, Casali PG and **Gronchi A**. Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. *Surg Oncol* 2016; 25(3): 125-131
 191. **Gronchi A**, Guadagnolo BA, Erinjeri JP. Local Ablative Therapies to Metastatic Soft Tissue Sarcoma. *Am Soc Clin Oncol Educ Book.* 2016;35:e566-e575
 192. Radaelli S, Stacchiotti S, Ruggieri P, Donati D, Casali PG, Palmerini E, Collini P, Gambarotti M, Porcu L, Boriani S, **Gronchi A**, Picci P. Sacral Chordoma: Long-Term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers. *Spine* 2016; 41(12):1049-1057.
 193. Ford S and **Gronchi A**. Indications for Surgery in Advanced/Metastatic GIST. *Eur J Cancer* 2016; 63: 154-167
 194. Grünwald V, Young R, Messiou C, Lia M, Wardelmann E, van der Graaf W, **Gronchi A**, Judson I for the EORTC STBSG. Absence of progression, not extent of remission tumour shrinkage defines prognosis in soft tissue sarcoma - an analysis of the EORTC 62012 study of the EORTC STBSG. *Eur J Cancer* 2016; 64:44-51.
 195. Ray-Coquard I, Litiere S, Rizzo E, Blay JY, Casali PG, Judson I, Krarup Hansen A, Lindner LH, Dei Tos AP, Gelderblom H, Marreaud S, Rutkowski P, Hohenberger P, **Gronchi A**, Van der Graaf WT. Impact of chemotherapy in Uterine Sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other Soft Tissue Sarcoma (STS) patients treated with first line chemotherapy. *Gynecol Oncol* 2016;142(1):95-101
 196. **Gronchi A**, Haas RL and Bonvalot S. Cancer Registries and randomized clinical trials in rare tumors: at the 2 extremes of daily clinical practice. *Eur J Cancer* 2016; 64:113-115
 197. Meazza C, Perrone F, Belfiore A, Busico A, Settanni G, Paielli N, Cesana L, Ferrari A, Chiaravalli S, **Gronchi A**, Colombo C, Pilotti S, Massimino A. AKT1 and BRAF mutations in pediatric aggressive fibromatosis. *Cancer Med* 2016; 5(6):1204-13
 198. Pasquali S, **Gronchi A**, Strauss D, Bonvalot S, Jeys L, Stacchiotti S, Hayes A, Honoré C, Collini P, Renne SL, Alexander N, Grimer RJ, Callegaro D, Sumathi VP, Gourevitch D, Desai A. Resectable extrapleural and extrameningeal Solitary Fibrous Tumor: a multi centre prognostic study. *Eur J Surg Oncol* 2016; 42:1064-1070
 199. Eastley N, McCulloch T, Esler C, Hennig I, Fairbairn J, **Gronchi A** and Ashford R. Extra-abdominal Desmoids Fibromatosis: a review of management, current guidance and unanswered questions. *Eur J Surg Oncol* 2016; 42:1071-1083
 200. Stacchiotti A, Provenzano S, Dagrada GP, Negri T, Brich S, Basso U, Brunelio A, Grosso F, Galli L, Palassini E, Libertini M, Colia V, **Gronchi A**, Dei Tos AP, Crippa F, Morosi C, Pilotti S and Casali PG. Sirolimus in advanced hemangioendothelioma: a retrospective case series analysis from the Italian Rare Cancer Network database. *Ann Surg Oncol* 2016; 23(9):2735-44
 201. van Broekhoven DL, Grünhagen DJ, van Dalen T, van Coevorden F, Bonenkamp HJ, Been LB, Bemelmans MH, Dijkstra SD, Colombo C, **Gronchi A**, Verhoef C. Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention. *BMC Cancer.* 2016;16(1):686
 202. Fiore M, MacNeill A, **Gronchi A**, Colombo C. Desmoid-type Fibromatosis: evolving treatment

- standards. *Surg Oncol Clin N Am* 2016; 25:803-826
203. Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult. A Consensus Approach from the Trans-Atlantic RPS Working group*. *Ann Surg Oncol* 2016; 23:3531-3540
 204. Stacchiotti S, Astolfi A, **Gronchi A**, Fontana A, Pantaleo MA, Negri T, Brenca M, Tazzari M, Urbini M, Indio V, Colombo C, Radaelli S, Brich S, Dei Tos AP, Casali PG, Castelli C, Dagrada GP, Pilotti S, Maestro R. Evolution of Dermatofibrosarcoma protuberans (DFSP) to DFSP-derived fibrosarcoma (FS-DFSP): an event marked by epithelial mesenchymal transition-like process and 22q loss. *Mol Cancer Res* 2016; 14(9):820-9
 205. Tseng WW, Pollock RE and **Gronchi A**. The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG): "Red wine or white"? *Ann Surg Oncol* 2016; 23(13):4418-4420
 206. **Gronchi A**, Delrio P, Quagliuolo V, Sandrucci S. The Italian Society of Surgical Oncology (SICO) survey on the minimum requirements of rare cancers referral centers. *Updates Surg* 2016; 68(4):321-323
 207. Belli F, **Gronchi A**, Corbellini C, Milione M and Leo E. Abdominosacral resection for locally recurring rectal cancer. *World J Gastrointest Surg* 2016; 8(12): 770-778.
 208. **Gronchi A**, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch S, Dei Tos AP, Collini P, Cruz Jurado J, De Paoli A, Donati DM, Poveda A, Quagliuolo A, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli S, Palassini E, Casali PG and Picci P. Short, Full-Dose Adjuvant Chemotherapy (CT) in High-Risk Adult Soft Tissue Sarcomas (STS): Long term Follow-Up of a Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. *Ann Oncol* 2016; 27(12):2283-2288
 209. Saponara M, Stacchiotti S, Casali PG and **Gronchi A**. (Neo)adjuvant treatment in localized soft tissue sarcoma (STS): the unsolved affair. *Eur J Cancer* 2017; 70:1-11
 210. **Gronchi A**, Maki RG, Jones RL. Treatment of soft tissue sarcoma: a focus on earlier stages. *Future Oncol.* 2017; 13(1s):13-21
 211. Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Boccone P, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf W, Touati N, Litière S, Marreud S, **Gronchi A**, Kasper B. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. *Acta Oncol* 2017; 56(1): 88-92
 212. Gasparotto D, Rossi S, Polano M, Tamborini E, Lorenzetto E, Sbaraglia M, Mondello A, Massani M, Lamon S, Bracci R, Mandolesi A, Frate E, Stanzial F, Agaj J, Mazzoleni G, **Gronchi A**, Dei Tos AP and Maestro R. Quadruple-negative GIST is a sentinel for unrecognized Neurofibromatosis Type 1 syndrome. *Clin Cancer Res* 2017; 23(1):273-282.
 213. Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, Fiore M, Stacchiotti S, Dagrada GP, Casali PG, **Gronchi A**, Astolfi A, Villa A, Lombardo C, Arienti F, Pilotti S, Rivoltini L, Castelli C. Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment. *J Invest Dermatol* 2017; 137:484-493
 214. Longhi A, Bielack SS, Grimer R, Whelan J, Windhager R, Leithner A, **Gronchi A**, Biau D, Jutte P, Krieg AH, Klenke FM, Grignani G, Donati DM, Capanna R, Casanova J, Gerrand C, Bisogno G, Hecker-Nolting S, De Lisa M, D'Ambrosio L, Willegger M, Scoccianti G and Ferrari S. Extraskelatal osteosarcoma: a European Musculoskeletal Oncology Society (EMSOS) study on 266 patients. *Eur J Cancer* 2017; 74:9-16
 215. Janssen ML, van Broekhoven DLM, Cates JMM, Bramer WM, Nuyttens JJME, **Gronchi A**, Baumert BG, Salas S, Bonvalot S, Ihalainen HR, Grunhagen DJ, Verhoef C. The Influence of Adjuvant Radiotherapy and Surgical Margin on Local Control After Resection of Sporadic Desmoid-type Fibromatosis: A Systematic Review and Meta-Analysis. *Br J Surg* 2017; 104(4):347-357
 216. Saponara M, Stacchiotti S and **Gronchi A**. Pharmacological therapies for Liposarcoma. *Exp Rev Clin Pharmacol* 2017; 10(4):361-377
 217. Stacchiotti S, M. Saponara, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, **Gronchi A**, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N. Patient-derived solitary fibrous tumor xenografts predict high sensitivity to Doxorubicin/Dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumor. *Eur J Cancer* 2017; 76:84-92.
 218. Sandrucci S, Trama A, Quagliuolo V, **Gronchi A**. Accreditation for centers of sarcoma surgery. *Updates Surg* 2017; 69(1):1-7
 219. Fiore M, Raut CP and **Gronchi A**. Are We Allowed to Limit Surgical Aggressiveness With Small Rectal Gastrointestinal Stromal Tumors? *Ann Surg Oncol* 2017; 24:1153-1156
 220. Delhorme JB, Fontana A, Levy A, Terrier P, Fiore M, Tzanis D, Callegaro D, Dratwa C, **Gronchi A**, Bonvalot S. Renal Angiomyolipomas: at Least Two Diseases. A Series of Patients Treated at Two European Institutions. *Eur J Surg Oncol* 2017; 43:831-836
 221. Palassini E, Frezza AM, Mariani L, Lalli L, Colombo C, Fiore M, Messina A, Casale A, Morosi C, Collini

- P, Stacchiotti S, Casali PG, **Gronchi A**. Long-term efficacy of methotrexate plus vinblastine/vinorelbine in large series of patients affected by desmoid-type fibromatosis. *Cancer J* 2017; 23: 86-91
222. Pantaleo MA, Urbini M, Indio V, Ravegnini G, Nannini M, De Luca M, Tarantino G, Angelini S, **Gronchi A**, Vincenzi B, Grignani G, Colombo C, Fumagalli E, Gatto L, Saponara M, Ianni M, Paterini P, Santini D, Pirini MG, Ceccarelli C, Altimari A, Gruppioni E, Renne SL, Collini P, Stacchiotti S, Brandi G, Casali PG, Pinna AD, Astolfi A, Biasco G. Genome-wide Analyses Identifies MEN1 and MAX Mutations and a Neuroendocrine-like Molecular Heterogeneity in Quadruple WT GIST. *Mol Cancer Res* 2017; 15(5):553-562
 223. Pasquali S and **Gronchi A**. Retroperitoneal Liposarcoma: an aggressive strategy to maximize disease control. *Int J Radiat Oncol Biol Phys* 2017; 98:273-274
 224. Urbini M, Astolfi A, Pantaleo MA, Serravalle S, Dei Tos AP, Picci P, Indio V, Sbaraglia M, Benini S, Righi A, Gambarotti M, **Gronchi A**, Colombo C, Dagrada GP, Pilotti S, Maestro R, Polano M, Saponara M, Tarantino G, Pession G, Biasco G, Casali PG, Stacchiotti S. HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma. *Gene Chrom Cancer* 2017; 56(7):582-586
 225. **Gronchi A**; Ferrari S Quagliuolo V; Martin Broto J; Lopez Pousa A; Grignani G; Basso U; Blay JY; Tendero O; Diaz Beveridge R; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bague S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P and Casali PG. Neoadjuvant Chemotherapy in High-risk Soft Tissue Sarcomas: A Randomized Clinical Trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG) and the Polish Sarcoma Group (PSG). *Lancet Oncol* 2017;18:812-822
 226. Casali PG, Zalcborg J, Le Cesne A, Reichardt P, Blay JY, Lindner L, Judson I, Schöffski P, Bauer J, Italiano A, Grünwald V, Lopez Pousa A, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn PCW, Litière S, Marreard S, Van der Graaf W, **Gronchi A**, Verweij J, on behalf of EORTC STBSG, ISG, AGITG. Ten-year progression-free and overall survival in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST). Long-term analysis of the EORTC, ISG, AGITG intergroup Phase III randomized trial on imatinib at two dose levels. *J Clin Oncol* 2017; 35:1713-1720
 227. Callegaro D, Miceli R and **Gronchi A**. Sarcoma nomograms: a light over the darkness. *Oncoscience* 2017; 4(3-4):15-16
 228. Young R, Litiere S, Lia M, Hogendoorn PCW, Fisher C, Mechtersheimer G, Daugaard S, Sciort R, Collin F, Messiou C, Grünwald V, **Gronchi A**, van der Graaf W, Wardelmann E, Judson I. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. *Acta Oncol* 2017; 56(7):1013-1020
 229. MacNeill AJ, Miceli R, Strauss DC, Bonvalot S, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, Casali PG, Pollock RE, Raut CP, **Gronchi A** and Swallow CJ. Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: a report from the Trans-Atlantic RPS Working Group (TARPSWG). *Cancer* 2017; 123(11):1971-1978
 230. Stacchiotti S, **Gronchi A**, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, P. Gardner A, Gelderblom H, Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, LA Vleggeert-Lankamp C, Casali PG, and Sommer J. Best practices for the Management of Local-regional Recurrent Chordoma. A Position Paper by the Chordoma Global Consensus Group. *Ann Oncol* 2017; 28:1230-1242
 231. Frezza AM, Stacchiotti S and **Gronchi A**. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. *BMC Medicine* 2017; 15:109
 232. Pasquali S, Palassini E, Stacchiotti S, Casali PG and **Gronchi A**. Neoadjuvant treatment: a novel standard? *Curr Opin Oncol* 2017; 29:253-259
 233. Pasquali S and **Gronchi A**. Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. *Ther Adv Med Oncol* 2017; 9(6):415-429
 234. Ford SJ, Almond LM and **Gronchi A**. An update on non-extremity soft tissue sarcomas. *Clin Oncol* 2017; 29:516-527
 235. Callegaro D, Miceli R, Mariani L, Raut CP and **Gronchi A**. Soft Tissue Sarcoma Nomograms and their Incorporation into Practice. *Cancer* 2017;123:2802-2820
 236. Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Onetti Muda A, **Gronchi A**, Casali, PG Dei Tos AP and Tonini G. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in

- advanced leiomyosarcoma and angiosarcoma. *Br J Cancer* 2017; 117:340-346
237. Tseng WW and **Gronchi A**. Surgery for Recurrence in Retroperitoneal Leiomyosarcoma: Is it All About Selection? *J Surg Oncol* 2017; 16(3):267-268.
 238. Frezza AM, Stacchiotti S and **Gronchi A**. Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting. *BMC Med* 2017; 15(1):160
 239. Colia V, Fiore M, Provenzano S, Fumagalli E, Bertulli R, Morosi C, Dei Tos AP, Barisella M, **Gronchi A**, Casali PG and Sanfilippo R. Activity of anthracycline and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma. *Clin Sarcoma Res* 2017; 7:16
 240. Urbini M, Astolfi A, Indio V, Tarantino G, Serravalle S, Saponara M, Nannini M, **Gronchi A**, Fiore M, Maestro R, Brenca M, Dei Tos AP, Dagrada GP, Negri T, Pilotti S, Casali PG, Biasco G, Pession A, Stacchiotti S, Pantaleo MA. Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. *Oncotarget* 2017; 8(36):60036-60045
 241. Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, Hohenberger P, Penel N, Messiou C, van der Graaf WT, **Gronchi A** on behalf of the Desmoid Working Group. An update on the management of sporadic Desmoid-Type Fibromatosis: a European consensus initiative between Sarcoma Patients Euronet (SPAEN) and European Organisation for Research and Treatment of Cancer (EORTC) / Soft Tissue and Bone Sarcoma Group (STBSG). *Ann Oncol* 2017; 28:2399-2408
 242. Colia V, Fumagalli E, Provenzano S, Bertulli R, Stacchiotti S, Morosi C, Collini P, **Gronchi A**, Casali PG and Sanfilippo R. High-dose Ifosfamide chemotherapy in a series of patients affected by myxoid liposarcoma. *Sarcoma* 2017; 2017:3739159
 243. De Sanctis R, Giordano L, Colombo C, De Paoli A, Navarria P, Sangalli C, Buonadonna A, Sanfilippo R, Bertola G, Fiore M, Marrari A, Navarria F, Bertuzzi A, Casali PG, Basso S, Santoro A, Quagliuolo V, **Gronchi A**. Long-term follow-up and post-relapse outcome of patients with localized retroperitoneal sarcoma treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STTS) Protocol 0303. *Ann Surg Oncol* 2017; 24:3872-3879
 244. Colombo C, Belfiore A, Paielli N, De Cecco L, Canevari S, Laurini E, Fermeglia M, Pricl S, Verderio P, Bottelli S, Fiore M, Stacchiotti S, Palassini E, **Gronchi A**, Pilotti S, Perrone F. B-catenin in Desmoid-Type Fibromatosis: deep insights on the role of T41A and S45F mutations on protein structure and gene expression. *Mol Oncol* 2017; 11(11):1495-1507
 245. Pastorino U, Scannagatta P, Girotti P, Rolli L, **Gronchi A**. Long-term results of thoraco-pleuro-pneumonectomy (TPP) for recurrent thoracic sarcomas. *Ann Surg Oncol* 2017; 24(Suppl 3):551-554
 246. Strauss DC, Renne SL and **Gronchi A**. Adjacent, Adherent, Invaded: a spectrum of biological aggressiveness rather than a rationale for selecting organ resection in surgery of primary retroperitoneal sarcomas. *Ann Surg Oncol* 2018;25(1):13-16
 247. Rossi S, Gasparotto D, Cacciatore M, Sbaraglia M, Mondello A, Polano M, Mandolesi A, **Gronchi A**, Reuss DE, von Deimling A, Maestro R and Dei Tos AP. Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs. *Mod Pathol* 2018;31(1):160-168
 248. Haas RL, **Gronchi A**, van de Sande MAJ, Baldini EH, Gelderblom H, Messiou C, Wardelmann E, Le Cesne A. Perioperative management of extremity soft tissue sarcomas. *J Clin Oncol* 2018;36(2):118-124
 249. Albertsmeier M, Rauch A, Roeder F, Hasenhütl S, Pratschke S, Kirschneck M, **Gronchi A**, Jebsen NL, Cassier PA, Sargos P, Belka C, Lindner LH, Werner J, Angele MK. External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma – a Systematic Review and Meta-Analysis. *Ann Surg Oncol* 2018; 25(3):754-767
 250. Corino VDA, Montin E, Messina A, Casali PG, **Gronchi A**, Marchiano A, Mainardi LT. Radiomic analysis of soft tissues sarcomas can distinguish intermediate from high-grade lesions. *J Magn Reson Imaging* 2018;47:829-840.
 251. Pasquali S, Colombo C, Pizzamiglio S, Verderio P, Callegaro D, Stacchiotti S, Martin Broto J, Lopez-Pousa A, Ferrari S, Poveda A, De Paoli A, Quagliuolo V, Cruz Jurado J, Comandone A, Grignani G, De Sanctis R, Palassini E, Llomboart-Bosch A, Dei Tos AP, Casali PG, Picci P, and **Gronchi A**. High-risk soft tissue sarcomas treated with perioperative chemotherapy: improving prognostic classification in a randomised clinical trial. *Eur J Cancer* 2018; 93:28-36
 252. Tseng WW, Pollock RE, **Gronchi A**. Retroperitoneal Sarcomas: Big tumors that Involve More than Just “Getting It Out”. *J Surg Oncol* 2018; 117:5-6
 253. Tseng WW, Pollock RE, **Gronchi A**. Historical Perspectives and Future Directions in the Surgical Management of Retroperitoneal Sarcoma. *J Surg Oncol* 2018; 117:7-11
 254. Paderno A, **Gronchi A** and Piazza C. Synovial Sarcoma of the upper aero-digestive tract: is there a role for conservative surgery. *Curr Opin Otolaryngol Head Neck Surg* 2018; 26(2):94-101
 255. Zanotti S, Kapetis D, Gibertini S, Salerno F, Ciusani E, Colombo C, **Gronchi A**, Morandi L, Mantegazza R, Molteni F, Mora M. Botulinum toxin type A affects the transcriptome of cell cultures derived from

- muscle biopsies of controls and spastic patients. *Toxicol in Vitro* 2018; 50:124-136
256. Verschoor AJ, Litiere S, Marreaud S, Judson I, Toulmonde M, Wardelmann E, van der Graaf WT, Le Cesne A, **Gronchi A**, Gelderblom H. Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study. *Eur J Cancer* 2018; 94:187-198
 257. MacNeill AJ, **Gronchi A**, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, Casali PG, Pollock RE, Barretta F, Raut CP and Strauss DC. Title: Post-operative morbidity after radical resection of primary retroperitoneal sarcoma: a report from the Transatlantic RPS Working Group (TARPSWG). *Ann Surg* 2018; 267(5):959-964
 258. Almond LM, **Gronchi A**, Strauss DC, Jafri M, Ford S, Desai A. Neoadjuvant and Adjuvant Strategies in Retroperitoneal Sarcoma. *Eur J Surg Oncol* 2018; 44:571-579
 259. Kasper B, Lecoite-Artznerb E, Waitc S, Boldond S, Wilson R, **Gronchi A**, Valverde C, Eriksson M, Dumont S, Drove N, Kanli A, Wartenberg M. Working to improve the management of sarcoma patients across Europe: a policy checklist. *BMC Cancer* 2018; 18(1):424
 260. Management of metastatic retroperitoneal sarcoma: a consensus approach from the Transatlantic Retroperitoneal Sarcoma Working Group (TARPSWG). *Ann Oncol* 2018; 29(4):857-871
 261. Fiore M, Ford S, Callegaro D, Sangalli C, Colombo C, Radaelli S, Frezza AM, Renne SL, Casali PG, **Gronchi A**. Adequate local control in high risk soft tissue sarcoma of the extremity treated with surgery alone at a reference center: should radiotherapy still be a standard? *Ann Surg Oncol* 2018; 25(6):1536-1543
 262. Lindner LH, Litière S, Sleijfer S, Benson C, Italiano A, Kasper B, Messiou C, Gelderblom H, Wardelmann E, Le Cesne A, Blay JY, Marreaud S, Hindi N, Desai IME, **Gronchi A**, van der Graaf WTA. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy. An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). *Int J Cancer* 2018; 42(12):2610-2620
 263. Benna C, Simioni A, Pasquali S, De Boni D, Rajendran S, Spiro G, Colombo C, Virgone C, Dubois S, **Gronchi A**, Rossi CR, Mocellin S. Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis. *Oncotarget* 2018;9(26):18607-18626
 264. Italiano A, Touati N, Litière S, Collin F, Pourquier P, **Gronchi A**. Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial. *Cancer Med* 2018; 7(5):1575-1577
 265. Jung E, Fiore M, **Gronchi A**, Grignol V, Pollock RE, Chopra, S, Chong SS, Hamilton AS, Tseng WW. Second Primary Malignancies in Patients with Well differentiated / Dedifferentiated Liposarcoma. *Anticancer Res* 2018; 38(6):3535-3542
 266. Issels RD, Lindner LH, Verweij J, Wessalowski R, Reichardt P, Wust P, Ghadjar P, Hohenberger P, Angele M, Salat C., Vujaskovic Z, Daugaard S, Mella O, Mansmann U., Dürr HR, Knösel T, Abdel-Rahman S., Schmidt M, Hiddemann W, Jauch KW, Belka K, and **Gronchi A**, for the European Organization for the Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group and the European Society for Hyperthermic Oncology. Neoadjuvant Chemotherapy Plus Regional Hyperthermia and Long-term Outcomes among Patients with Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. *Jama Oncol* 2018;4(4):483-492
 267. Tseng WW, Tsao-Wei DD, Callegaro D, Grignani G, D'Ambrosio L, Bonvalot S, Ethun CG, Cardona K, Mullen JT, Canter RJ, Mullinax JE, Gonzalez RJ, van Coevorden F, Albertsmeier M, Dhanireddy KK, Renne SL, **Gronchi A**. Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma. *Eur J Surg Oncol* 2018 Jun;44(6):810-815
 268. Touati N, Schöffski P, Litière S, Judson I, Sleijfer S, van der Graaf WT, Italiano A, Isambert N, Gil T, Blay JY, Stark D, Brodowicz T, Marréaud S, **Gronchi A**. EORTC Soft Tissue and Bone Sarcoma Group (STBSG) experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: clinical profile and response to systemic therapy. *Clin Oncol* 2018; 30:448-454
 269. **Gronchi A** Crago A and Raut CP. Minimally Invasive Surgery for Retroperitoneal Sarcoma: Just Because We Can Does Not Mean We Should. *Ann Surg Oncol* 2018; 25:2129-2131
 270. Tattersall HL and **Gronchi A**. Surgical Resection as an Adjuvant to Tyrosine Kinase Inhibitors in Metastatic GIST: Association or Causation? / Are we any closer to an answer? *Eur J Surg Oncol* 2018; 44:1287-1288
 271. Rutkowski P, Gaston L, Borkowska A, Stacchiotti S, Gelderblom H, Baldi GG, Palmerini E, Casali PG, **Gronchi A**, Parry M, Campanacci DA, Scoccianti G, Wagrodzki M, Ferrari S, Dijkstra S, Pieńkowski A, Grimer R. Denosumab treatment of inoperable or locally advanced Giant Cell Tumor of Bone - multicenter analysis outside clinical trial. *Eur J Surg Oncol* 2018; 44:1384-1390
 272. **Gronchi A**. Towards the standard use of (Neo)adjuvant chemotherapy in selected localized soft

- tissue sarcoma at high risk of relapse: are we finally getting there? *Eur J Cancer* 2018; 101:251-253
273. Urbini M, Indio V, Astolfi A, Tarantino G, Renne SL, Pilotti S, Dei Tos AP, Maestro R, Collini P, Nannini M, Saponara M, Murrone L, Dagrada P, Colombo C, **Gronchi A**, Pession A, Casali PG, Stacchiotti S, Pantaleo M. Identification of an actionable mutation of Kit in a case of extraskeletal myxoid chondrosarcoma. *Int J Mol Science* 2018 Jun 23;19(7). pii: E1855
 274. Levy A, Bonvalot S, Callegaro D, Botticella A, Le Cesne A, **Gronchi A** and Le Pechoux C. Consistent margin status reporting in soft tissue sarcoma essential to establish risk adapted strategies integrating biology and histotype in perioperative treatments. *J Clin Oncol* 2018; 36(22):2357-2358
 275. Colombo C, Urbini M, Astolfi A, Collini P, Belfiore A, Paielli N, Perrone F, Indio V, Tarantino G, Palassini E, Fiore M, Stacchiotti S, Pantaleo MA, **Gronchi A**. Novel intra-genic large deletions of CTNNB1 gene identified in WT desmoid-type fibromatosis. *Gene Chrom Cancer* 2018; 57(10):495-503
 276. Sleijfer S, Rizzo E, Litière S, Mathijssen RHJ, Judson IR, Gelderblom H, Van Der Graaf WTA, **Gronchi A**. Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-Soft Tissue and Bone Sarcoma Group database. *Acta Oncol* 2018; 57(8):1117-1126
 277. Frezza AM, Lee ATJ, Nizri E, Sbaraglia M, Jones RL, **Gronchi A**, Dei Tos AP, Casali PG. 2018 ESMO Sarcoma and GIST Symposium: 'take-home messages' in soft tissue sarcoma. *ESMO Open* 2018; 3(4):e000390
 278. Tattersall HL, Callegaro D, Ford SJ, **Gronchi A**. Staging, Nomograms and Other Predictive Tools in Retroperitoneal Soft Tissue Sarcoma. *Chin Clin Oncol* 2018; 7(4):36
 279. Wang J, Grignol VP, **Gronchi A**, Luo CH, Pollock RE, Tseng WW. Surgical Management of Retroperitoneal Sarcoma and Opportunities for Global Collaboration. *Chin Clin Oncol* 2018; 7(4):39
 280. Dumitra S and **Gronchi A**. The diagnosis and management of retroperitoneal sarcoma. *Oncology* 2018; 32(9):464-469
 281. Frezza AM; Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desai IME, Benjamin RSE, Blay JY, Martin Broto J, Casali PG, Gelderblom H, Grignani G, **Gronchi A**, Sundby Hall K, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Terrier P, Picci P, Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S. Anthracycline, gemcitabine and pazopanib in epithelioid sarcoma: results of a retrospective multi-institutional case series. *Jama Oncol* 2018; 4(9):e180219
 282. **Gronchi A** and Jones RL. The value of neoadjuvant chemotherapy in localized high risk soft tissue sarcoma of the extremities and trunk. *JAMA Oncol* 2018; 4(9):1167-1168
 283. Casali PG, Bielack S, Abecassis N, Haro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Brennan B, Broto JM, Brugieres L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, **Gronchi A**, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY, on behalf of the ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018; 29 (Supplement 4): iv79-iv95
 284. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, **Gronchi A**, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018; 29 (Supplement 4): iv68-iv78
 285. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, **Gronchi A**, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski

- P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018; 29 (Supplement 4): iv51-iv67
286. Younger E, Litière S, Le Cesne A, Mir O, Gelderblom H, Italiano A, Marreaud S, Jones RL, **Gronchi A**, van der Graaf WT. Outcomes of elderly advanced soft tissue sarcoma patients treated with first-line chemotherapy: a pooled analysis of twelve EORTC Soft Tissue and Bone Sarcoma Group trials. *The Oncologist* 2018; 23(10):1250-1259
 287. Savina M, Litière S, Italiano A, Burzykowski T, Bonnetain F, Gourgou S, Rondeau V, Blay JY, Cousin S, Duffaud F, Gelderblom H, **Gronchi A**, Judson I, Le Cesne A, Lorigan P, Maurel J, van der Graaf W, Verweij J, Mathoulin-Pelissier S, Bellera C. Surrogate endpoints in advanced sarcoma trials: a meta-analysis. *Oncotarget* 2018; 9(77):34617-34627
 288. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Le Pèchoux C, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Catton C, Casali PG, 10, Wunder JS, **Gronchi A**. Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centers. *Eur J Cancer* 2018; 105:19-27
 289. Stacchiotti S, Morosi C, Lo Vullo S, Casale A, Palassini E, Frezza AM, Dinoi G, Messina A, **Gronchi A**, Morelli D, Cavalleri A, Venturelli E, Pilotti S, Collini P, Brich S, Tamborini E, Mariani L, Casali PG. Imatinib in combination with everolimus in patients with progressing advanced chordoma: a Phase 2 clinical study. *Cancer* 2018; 124(20):4056-4063
 290. Raut CP, Bonvalot S and **Gronchi A**. A Call to Action: Why Sarcoma Surgery Needs to be Centralized. *Cancer* 2018; 124(23):4452-4454
 291. Giannini L, Incandela F, Fiore M, **Gronchi A**, Stacchiotti S, Sangalli C and Piazza C. Radiation Induced Sarcoma of the Head and Neck: a review of the literature. *Front Oncol* 2018 Oct 17;8:449
 292. Fiore M and **Gronchi A**. ASO Author Reflections: Evolving Concepts for Radiation Therapy in Extremity and Trunk Soft Tissue Sarcoma. *Ann Surg Oncol* 2018; 25(Suppl 3):942-943
 293. Stacchiotti S, Simeone N, Lo Vullo S, Morosi C, Greco FG, **Gronchi A**, Barisella M, Collini P, Zaffaroni N, Dagrada GP, Frezza AM, Mariani L, Casali PG. Activity of axitinib in progressive advanced solitary fibrous tumor: results from an exploratory, investigator-driven Phase 2 clinical study. *Eur J Cancer* 2019; 106:225-233
 294. Gonzato O and **Gronchi A**. The evolving role of patient advocates in rare cancers: opportunities and challenges. *Expert Rev Pharmacoecon Outcomes Res* 2019; 19(1):1-3
 295. Pasquali S, Bonvalot S, Tzanis D, Casali PG, Trama A, **Gronchi A**. Treatment challenges in and outside a network setting: soft tissue sarcomas. *Eur J Surg Oncol* 2019; 45:31-39
 296. Pasquali S, Pizzamiglio S, Touati N, Litière S, Marreaud S, Kasper B, Gelderblom H, Stacchiotti S, Judson I, Dei Tos AP, Verderio P, Casali PG, Woll PJ and **Gronchi A**, on behalf of the EORTC - Soft Tissue and Bone Sarcoma Group. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomized trial. *Eur J Cancer* 2019; 109:51-60
 297. Nizri E, Fiore M, Colombo C, Radaelli S, Callegaro D, Sanfilippo R, Sangalli C, Collini P, Morosi C, Stacchiotti S, Casali PG, **Gronchi A**. Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas achieves comparable oncological outcomes- a propensity score analysis. *J Surg Oncol* 2019; 119:318-323
 298. Pastorino U, Morelli D, Leuzzi G, Rolli aL, Suatoni P, Taverna F, Bertocchi E, Boeri M, Sozzi G, Cantarutti A, Corrao G, **Gronchi A**. Baseline and postoperative C-reactive protein levels predict long-term survival after lung metastasectomy. *Ann Surg Oncol* 2019; 26(3):869-875
 299. Almond LM, Tirota F, Tattersall H, Hodson J, Cascella T, Barisella M, Marchianò A, Greco G, Desai A, Ford SJ, **Gronchi A**, Fiore M, Morosi C. Diagnostic Accuracy of Percutaneous Biopsy in Retroperitoneal Sarcoma. *Br J Surg* 2019; 106(4):395-403
 300. Mir O, Touati N, Lia M, Litière S, Le Cesne A, Sleijfer S, Blay JY, Leahy M, Young R, Mathijssen R, Van Erp NP, Gelderblom AJ, Van der Graaf WT, **Gronchi A**. Impact of concomitant administration of gastric acid suppressive agents and pazopanib on outcomes in soft tissue sarcoma patients treated within EORTC 62043/62072 trials. *Clin Cancer Res* 2019; 25(5):1479-1485
 301. Haas RL, Bonvalot S, Miceli R, Strauss DC, Swallow CJ, Hohenberger P, van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Gladdy R, Jakob J, Szacht M, Fiore M, Chung PW, van Houdt WJ, Raut CP, **Gronchi A**. Radiation Therapy for Retroperitoneal Liposarcoma - a report from TARPSWG. *Cancer* 2019;125:1290-1300
 302. **Gronchi A** and Jones RL. Treatment of Desmoid Tumor in 2019. *JAMA Oncol* 2019;5(4):567-568
 303. Raut CP, Callegaro D, Miceli R, Barretta F, Rutkowski P, Blay JY, Lahat G, Strauss DC, Gonzalez R, Ahuja N, Grignani G, Quagliuolo V, Stoeckle E, De Paoli A, Pillarisetty VG, Nessim C, Swallow CJ,

- Bagaria S, Canter R, Mullen J, Gelderblom HJ, Pennacchioli E, van Coevorden F, Cardona K, Fiore M, Fairweather M, **Gronchi A**. Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. *Clin Cancer Res* 2019; 25(8):2664-2671
304. **Gronchi A**, Hindi N, Cruz J, Blay JY, Lopez-Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón I, Sangalli C, Pérez Aguiar JL, Romero J, Morosi C, Sunyach MP, Sanfilippo R, Romagosa C, Ranchere-Vince D, Dei Tos AP, Casali PG, Martin-Broto J. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): results of a phase I study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. *EClinicalMedicine* 2019; 9:35-43
 305. Ferraris M, Callegaro D, Barretta F, Fiore M, Radaelli S, Stacchiotti S, Miceli R, Socrate AM, Locati P, **Gronchi A**. Outcome of iliocaval resection and reconstruction for retroperitoneal sarcoma. *J Vasc Surg Venous Lymphat Disord* 2019; 7:547-556.
 306. Van Houdt W, Raut CP, Bonvalot S, Swallow CJ, Haas RL and **Gronchi A**. New research strategies in retroperitoneal sarcoma: the case of TARPSWG, STRASS and RESAR - making progress through collaboration. *Curr Opin Oncol* 2019; 31(4):310-316
 307. Tirotta F, Fumagalli E, Colombo C, Morosi C, Barisella M, Radaelli S, Frezza AM, Casali PG, **Gronchi A**, Fiore M. Management of complicated tumor response to tyrosine kinase inhibitors in gastrointestinal stromal tumors (GIST), *J Surg Oncol* 2019;120:256-261
 308. Fucà G, Hindi N, Ray-Coquard I, Colia V, Dei Tos AP, Martin-Broto J, Brahmi M, Collini P, Lorusso D, Raspagliesi F, Pantaleo MA, Vincenzi B, Fumagalli E, **Gronchi A**, Casali PG, Sanfilippo R. Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. *The Oncologist* 2019;24:e536-e541
 309. Brenca M, Stacchiotti S, Fassetta K, Sbaraglia M, Janjusevic M, Racanelli D, Polano M, Rossi S, Brich S, Dagrada GP, Collini P, Colombo C, **Gronchi A**, Astolfi A, Indio V, Pantaleo MA, Picci P, Casali PG, Dei Tos AP, Pilotti S, Maestro R. NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas. *J Pathol* 2019; 249:90-101
 310. Suarez-Kelly LP, Baldi GG and **Gronchi A**. Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments. *Exp Opin Pharmacother* 2019; 20(12):1503-1515
 311. Dingley B, Fiore M and **Gronchi A**. Personalizing surgical margins in retroperitoneal sarcomas: an update. *Exp Rev Anticancer Ther* 2019; 19(7):613-631
 312. Stacchiotti S, Zuco V, Tortoreto M, Cominetti D, Frezza AM, Percio S, Indio V, Barisella M, Monti V, Brich S, Astolfi A, Colombo C, Pasquali S, Folini M, Gounder M, Pantaleo MA, Collini P, Dei Tos AP, Casali PG, **Gronchi A**, Zaffaroni N. Comparative assessment of antitumor effect and autophagy induction as resistance mechanism by cytotoxics and EZH2 inhibition in INI1-negative epithelioid sarcoma patient-derived xenograft. *Cancers* 2019; 11(7). pii: E1015
 313. Bonvalot S, Rutkowski PL, Thariat J, Carrère S, Ducassou A, Sunyach MP, Agoston P, Hong A, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco B, Herraes AC, **Gronchi A**, Mangel L, Sy-Ortin T, Hohenberger P, de Baère T, Le Cesne A, Helfre S, Saada-Bouزيد E, Borkowska A, Anghel R, Co A, Gebhart M, Kantor G, Montero A, Loong HH, Vergés R, Lapeire L, Dema S, Kacso G, Austen L, Moureau-Zabotto L, Servois V, Wardelmann E, Terrier P, Lazar AJ, Bovée JVMG, Le Péchoux C, Papai Z. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. *Lancet Oncol* 2019; 20(8):1148-1159
 314. Hohenberger P, Bonvalot S, van Coevorden F, Rutkowski P, Stoeckle E, Olungu C, Litiere S, Wardelmann E, **Gronchi A**, Casali PG. Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study. *Eur J Cancer* 2019; 120:47-53
 315. Tseng WW, Pasquali S, Hu JS, Menendez LR, **Gronchi A**. Staging Systems and Nomograms in Soft Tissue Sarcoma: Outcome Prediction by Categorization or Personalization? *Chin Clin Oncol* in press
 316. Sanfilippo R; Jones R; Blay JY; LeCesne A; Provenzano S; Antoniou G; Mir O; Fucà G; Fumagalli E; Bertulli R; Stacchiotti S; Brahmi M; Grosso F, Dufresne A; Hindi N; **Gronchi A**; Collini P; Dei Tos AP; Casali PG. Role of chemotherapy, VEGFR inhibitors and mTOR Inhibitors in advanced Perivascular Epithelioid Cell Tumours (PEComas). *Clin Cancer Res* in press
 317. Nizri E, Fiore M, Barretta F, Colombo C, Radaelli S, Callegaro D, Sanfilippo R, Sangalli C, Collini P, Stacchiotti S, Casali PG, Miceli R, **Gronchi A**. Intraperitoneal invasion of retroperitoneal sarcomas- a risk factor for dismal prognosis. *Ann Surg Oncol* in press
 318. Frezza AM, Assi T, Lo Vullo S, Ben-Amy E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Tetery P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desar I, Fedenko A, Maki RG, Jones R, Benjamin RS, Blay JY, Kawai A, Gounder M, **Gronchi A**, Le Cesne A, Mir O, Czarnecka AM, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A,

Mariani L, Casali PG, Thornton K, Stacchiotti S. Systemic treatments in MDM2 positive intimal sarcoma: a multicentre experience with anthracycline, gemcitabine and pazopanib within the World Sarcoma Network (WSN) Cancer in press

319. Bello E, Brich S, Craparotta I, Mannarino L, Ballabio S, Gatta R, Marchini S, Carrassa L, Matteo C, Sanfilippo R, **Gronchi A**, Casali PG, Pilotti S, D'Incalci M, and Frapolli R. Establishment and characterization of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin. Br J Cancer in press
320. Frapolli R, Bello E, Ponzo M, Craparotta I, Mannarino L, Ballabio S, Marchini S, Carrassa L, Ubezio P, Porcu L, Brich S, Sanfilippo R, Casali PG, **Gronchi A**, Pilotti S, and D'Incalci M. Combination of PPAR γ agonist pioglitazone and trabectedin overcomes resistance against trabectedin in myxoid liposarcomas by induction of adipocytic differentiation. Clin Cancer Res in press

- Elenco capitoli di libro in lingua inglese

1. **Gronchi A** and Fiore M. Chordoma. In Khatri VP ed: Clinical Scenarios in Surgical Oncology. Philadelphia: Lippincott Williams & Wilkins; 2006: 299-302.
2. Santinami M, **Gronchi A**, Maurichi M, Zoras O, Patuzzo R, Pennacchioli E. Limb's perfusion: rationale, techniques and results. In Zoras O ed: Regional Oncotherapies. Athens: Paschalidis Medical Publications Ltd; 2006:193-226.
3. **Gronchi A**, Colombo C and Fiore M. Surgery of Primary Tumor. In Blay JY ed: 100 Key Questions on Soft Tissue Sarcoma. Mallorca: Permanyer Publications; 2010: 55-67.
4. **Gronchi A**, Fiore M, Palaia R. Surgical Treatment. In de Lutio di Castelguidone E and Messina A eds: GISTs - Gastrointestinal Stromal Tumors. Milan: Springer Verlag Italia; 2011: 107-112.
5. Fletcher CDM, Singer S, **Gronchi A**. Tumor of Soft Tissue: Introduction. In Fletcher CDM, Bridge JA, Hogendoorn PCW and Mertens F eds: WHO Classification of Tumours of Soft Tissue and Bone. Lyon; IARC; 2013: 14-16
6. **Gronchi A**. Surgical Management of Soft Tissue Sarcomas. In Blay JY ed. Atlas of data and images on STS. Madrid; Grupo Editorial Entheos. 2013: 177-231
7. Raut CP and **Gronchi A**. The management of Soft Tissue Sarcoma. In Cameron JL and Cameron AM eds: Current Surgical Therapy. Philadelphia: Elsevier Saunders; 2014: 706-717
8. Comier JN, **Gronchi A** and Pollock RE. Soft Tissue Sarcoma. In Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB, Pollock RE eds: Schwartz's Principles of Surgery. New York: McGraw-Hill Professional; 2014: 1465-1493
9. Casali PG, Dei Tos AP and **Gronchi A**. Gastrointestinal Stromal Tumor. In DeVita, Hellman, and Rosenberg eds: Cancer. Principles & Practice of Oncology. Philadelphia Wolters Kluwer Health; 2015: 745-756
10. **Gronchi A**, Dei Tos AP, Casali PG. Sarcomas of Soft Tissue and Bone. In Kerr DJ, Haller DG, van de Velde CJH, Baumann M eds: Oxford Textbook of Oncology. Oxford: Oxford University Press; 2016: 844-866
11. Fontana A, Callegaro D and **Gronchi A**. Standard of care in early phases. In Blay JY ed: 100 Key Questions on Soft Tissue Sarcoma. Mallorca: Permanyer Publications; 2016: 17-28
12. Sandrucci S, Stacchiotti S and **Gronchi A**. Retroperitoneal Sarcoma. In Poston G, Wyld L, Audisio RA eds: Surgical Oncology. Theory and Multidisciplinary Practice. Boca Raton: CRC Press Taylor & Francis Group; 2017: 617-629
13. Fiore M, Radaelli S and **Gronchi A**. Retroperitoneal Sarcoma involving the Inferior Vena Cava. In Azoulay D, Lim C, Salloum eds: Surgery of the Inferior Vena Cava: multidisciplinary approach. Cham: Springer International Publishing Switzerland; 2017: 61-74
14. Radaelli S, Colombo C, Fiore M and **Gronchi A**. Soft Tissue Tumors of the Groin and Inguinal region. In Delman KA and Master VA eds: Malignancies of the Groin. Springer International Publishing Switzerland; 2017: 123-157
15. Quagliuolo V and **Gronchi A**. Eds. Current treatment of Retroperitoneal Sarcoma: a joint effort with the Italian Society of Surgical Oncology. Springer-Verlag Italia; 2018
16. Casali PG, Dei Tos AP and **Gronchi A**. Gastrointestinal Stromal Tumor. In DeVita, Hellman, and Rosenberg eds: Cancer. Principles & Practice of Oncology. Philadelphia Wolters Kluwer Health; 2019: 895-906
17. Gonzalez RJ, **Gronchi A** and Pollock RE. Soft Tissue Sarcoma. In Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Kao LS, Matthews JB, Pollock RE eds: Schwartz's Principles of Surgery. New York: McGraw-Hill Professional; 2019: 1567-1598
18. **Gronchi A**. Principles of Local Therapy of Soft Tissue Neoplasms. In Dei Tos AP ed: Soft Tissue Sarcomas: A Pattern-Based Approach to Diagnosis. Cambridge: Cambridge University Press United

- Finanziamenti Competitivi in qualità di responsabile del progetto
 1. PRINCIPAL INVESTIGATOR. Tailored beta catenin mutational approach in extra-abdominal desmoid tumor patients: an observational study. **Funded by Ricerca Finalizzata RF2009-1511297 (293600 €)**. Clinicaltrial.gov NCT02547831 dal 01-01-2013 al 30/11/2015
 2. PRINCIPAL INVESTIGATOR. Localized High-Risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults: an Integrating Approach Comprising Standard vs Histotype-Tailored Neoadjuvant Chemotherapy. A prospective controlled randomized trial from Italian Sarcoma Group, Spanish Sarcoma Group, French Sarcoma Group, Polish Sarcoma Group. Closed by May 2016. Reported at ESMO as oral presentation (late-breaking abstract) in 2017 and at ASCO as oral presentation in 2019. Preliminary data published in Lancet Oncol in 2017. **Funded by a European Union Grant: Eurosarc FP7 278472 (440966 €)**. Clinicaltrial.gov NCT01710176 dal 19-05-2011 al 31/5/2018
- Organizzazione, direzione e Coordinamento di gruppi di ricerca nazionali ed internazionali e/o società scientifiche o partecipazione agli stessi
 1. Membro del Consiglio Direttivo della Connective Tissue Oncology Society (a non-profit professional medical organization whose members are a multidisciplinary group of specialized physicians, medical professionals, and scientists from around the world to connect, collaborate, and share their knowledge, experiences, and research for the advancement of treatment of sarcomas. It's based in Alexandria - United States) dal 1/2009 al 12/2017. Durante tale periodo ha ricoperto le cariche di Tesoriere dal 1/2013 al 12/2013, Segretario dal 1/2014 al 12/2014, Vice Presidente dal 1/2015 al 12/2015, **Presidente dal 1/2016 al 12/2016** e Past President dal 1/2017 al 12/2017.
 2. Membro del Consiglio direttivo del Soft Tissue and Bone Sarcoma Group dell'European Organization for Research and Treatment in Cancer (EORTC- Bruxelles - Belgium) dal 2010 al 2019, ricoprendo le cariche di segretario dal 7/2010 al 6/2013, vice responsabile dal 7/2013 al 12/2014, **Coordinatore dal 1/2015 al 12/2017**, Coordinatore Passato dal 1/2018 al 7/2019.
 3. **Presidente** in carica della Società Italiana di Chirurgia Oncologica a partire dal 9/2019 per il biennio 2019-2021.
 4. **Fondatore e coordinatore** del Trans-atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) dal 12/2013.
 5. **Membro** dell'Editorial Board della WHO Classification of Soft Tissue and Bone Tumours group alla International Agency for Research on Cancer (IARC) in Lyon, France. 2019
 6. Membro dell' International Committee della Society of Surgical Oncology (SSO) 4/2009-3/2011
 7. Membro del Sarcoma Disease Site Working Group della Society of Surgical Oncology (SSO) 4/2018-3/2021
 8. Rappresentante Internazionale del Nominating Committee della Society of Surgical Oncology (SSO) 4/2019-3/2020
 9. Membro del Consiglio direttivo dell'Italian Sarcoma Group dal 1/1/2003 ad oggi
- Direzione o partecipazione a comitati editoriali di riviste scientifiche
 1. Associate Editor Annals of Surgical Oncology dal 1/1/2009 al 31/12/2014 e dal 1/7/2018 ad oggi
 2. Associate Editor Critical Reviews in Oncology/Hematology dal 1/5/2019 ad oggi
 3. Associate Editor di Journal of Surgical Oncology dal 1/3/2017 ad oggi
 4. Associate Editor di Sarcoma Journal dal 1/1/2013 ad oggi
 5. Associate Editor di Clinical Sarcoma Research dal 1/1/2014 ad oggi
 6. Associate Editor di Tumori Journal dal 1/1/2015 ad oggi
- Visiting professor
 1. Visiting Professor in Surgical Oncology at the Huntsman Cancer Institute, University of Utah, United States. 1-3/11/2011
 2. Visiting Professor in Surgical Oncology at the Harvard University - Dana Farber Cancer Institute and Brigham Women's Hospital - Boston - United States. 17-19/09/2012
 3. Visiting Professor in Surgical Oncology at the University Hospital Birmingham, Queen Elizabeth Hospital - Birmingham - United Kingdom. 25-26/03/2013
 4. Visiting Professor in Surgical Oncology at the MD Anderson Cancer Center - Houston - United States. 28-30/05/2013
 5. The Edward J. Tabah Visiting Professor in Surgical Oncology at the McGill University Health Center (MUHC). Cedars Cancer Foundation, Montréal, Québec, Canada 26-27/04/2017.
 6. Visiting Professor in Surgical Oncology at the Ohio State University - Columbus - United States. 14-

15/03/2018

7. Daniels Visiting Professor in Surgical Oncology at the University of Toronto - Mount Sinai Hospital Toronto - Canada 26-30/05/2019

- Conseguimento di Premi/Riconoscimenti Nazionali e Internazionali per attività di ricerca

1. Honorary Guest to the Meeting on Abdominal Sarcoma. Ege Surgical Society, Izmir, Turkey. dal 13-10-2012 al 13-10-2012
2. Distinguished Invited Lecturer. Annual Scientific Congress, Brisbane 2016. Royal Australasian College of Surgeons. 04/05/2016
3. Honorary Membership of Polish Society of Surgical Oncology (PSSO) dal 19/05/2017 a oggi

- Partecipazione in qualità di relatore a congressi e convegni di interesse internazionale

1. CONNECTIVE TISSUE ONCOLOGY SOCIETY ANNUAL MEETING 2003, Oral presentation: Soft tissue sarcoma of the extremities: quality of margins and survival in 1000 plus patients treated at a single institution. 06-08/11/2003.
2. CONNECTIVE TISSUE ONCOLOGY SOCIETY ANNUAL MEETING 2004, Oral Presentation: Validation and adaption of a nomogram for predicting survival of extremity STS using a 3 grade system. 11-13/11/2004.
3. SOCIETY OF SURGICAL ONCOLOGY ANNUAL MEETING 2005, Oral Sarcoma Session: Prognostic effect of re-excision in adult STS of extremity. 03-05/03/2005.
4. GRUPO ESPANOL DE INVESTIGACION EN SARCOMAS ANNUAL MEETING 2005, Tratamiento quirúrgico en la enfermedad avanzada y tumores retroperitoneales. 04-11-2005
5. CONNECTIVE TISSUE ONCOLOGY SOCIETY ANNUAL MEETING 2005. 2 Oral presentations: 1) A European project for surgical margins assessment in soft tissue sarcoma of the extremities and superficial trunk; 2) Advanced Gastrointestinal Stromal Tumor: Molecular, pathological and clinical patterns in post-imatinib surgery. 19-21/11/2005
6. CONNECTIVE TISSUE ONCOLOGY SOCIETY ANNUAL MEETING 2006. Oral presentation: Correlation between histology and KIT/PDGFR gene status in imatinib treated Gastrointestinal Stromal Tumors (GIST). 02-04/11/2006
7. GRUPO ESPANOL DE INVESTIGACION EN SARCOMAS ANNUAL MEETING 2007. Oral presentation: Surgical Techniques in Soft Tissue Sarcomas. 23-03-2007
8. POLISH SOCIETY OF SURGICAL ONCOLOGY ANNUAL MEETING 2007. 2 Oral presentations: 1) Combined modalities in extremity soft tissue sarcoma; 2) Combined modalities in retroperitoneal soft tissue sarcoma. 18-05-2007
9. EUROPEAN SOCIETY OF MEDICAL ONCOLOGY (ESMO) ANNUAL MEETING 2008. Oral presentation: Controversy in regional hyperthermia for Soft Tissue Sarcoma. 12-16/09/2008
10. CONNECTIVE TISSUE ONCOLOGY SOCIETY ANNUAL MEETING 2008. Oral presentation: Marginal surgery in primary extremity soft tissue sarcoma: prognostic role of anatomic barrier at closest surgical margin. 13-15/11/2008.
11. AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING 2009. Oral presentation: Retroperitoneal soft tissue sarcoma: multivisceral resection and iterative surgery. 28/05-02/06/2009.
12. Joint EUROPEAN CONFERENCE of CLINICAL ONCOLOGY (ECCO) 15 - 34th ESMO MULTIDISCIPLINARY CONGRESS 2009. Oral presentations: 1) How to choose your treatment options for desmoids; 2) A Phase II Clinical Trial Of Neoadjuvant Trabectedin In Patients With Non Metastatic Advanced Myxoid / Round Cell Liposarcoma (MRCL). 20-24/09/2009.
13. CONNECTIVE TISSUE ONCOLOGY SOCIETY ANNUAL MEETING 2009. Oral presentation: Subtype specific post-operative nomogram for patients affected by primary retroperitoneal soft tissue sarcoma. 05-07/11/2009
14. EUROPEAN MUSCULO-SKELETAL ONCOLOGY SOCIETY (EMSOS) ANNUAL MEETING 2010. Oral presentation: Extremity Liposarcoma: Local Control and FU. 05-07/05/2010.
15. AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING 2010. Oral presentation: Localized high risk soft tissue sarcoma of the extremities and trunk wall in adults: 3 vs 5 cycles of full dose anthracycline and ifosfamide adjuvant chemotherapy: a phase III randomized trial from the Italian Sarcoma Group and the Spanish Sarcoma Group 04-08/06/2010.
16. BRITISH SARCOMA GROUP ANNUAL MEETING 2010. Oral presentations: 1) Local recurrence after treatment of extremity soft tissue sarcoma kills patients; 2) What is the value of aggressive visceral resection in the retroperitoneal sarcomas? 15-06-2010
17. EUROPEAN SOCIETY OF SURGICAL ONCOLOGY (ESSO) ANNUAL MEETING 2010. Oral presentation:

- Surgical Margins, local recurrence and salvage techniques in soft tissue sarcomas. 15-17/09/2010.
18. EUROPEAN SOCIETY OF MEDICAL ONCOLOGY (ESMO) ANNUAL MEETING 2010, Oral presentations: 1) Genotyping GIST for clinical decision-making, Tailoring the scalpel; 2) ESMO Clinical Recommendations Session: GIST. 08-12/10/2010
 19. GRUPO ESPANOL DE INVESTIGACION EN SARCOMAS ANNUAL MEETING 2010. Oral presentations: 1) Surgery in Neoadjuvant Treatment of Soft Tissue Sarcoma; 2) Neoadjuvant Therapy and Surgery of the Advanced GIST. 05-11-2010
 20. CONNECTIVE TISSUE ONCOLOGY SOCIETY ANNUAL MEETING 2010. Oral presentation: Resection of clinically uninvolved adjacent viscera as part of surgery for primary retroperitoneal soft tissue sarcoma is associated to improved local control and survival 11-13/11/2010.
 21. EUROPEAN MULTIDISCIPLINARY CANCER CONFERENCE (EMCC) 2011 (ECCO ESMO ESTRO). Oral presentations: 1) Preoperative Chemotherapy is standard of care in soft tissue sarcoma; 2) Desmoid-type fibromatosis – How much surgery and when. 23-27/09/2011.
 22. CONNECTIVE TISSUE ONCOLOGY SOCIETY ANNUAL MEETING 2011 Oral presentation: Preoperative chemo-radiation therapy for localized retroperitoneal soft tissue sarcoma (STS): a phase II study from the Italian Sarcoma Group. 26-29/10/2011.
 23. EUROPEAN MUSCOLO-SKELETAL ONCOLOGY SOCIETY (EMSOS) ANNUAL MEETING 2012. Oral presentations: 1) Preoperative Chemo-radiation therapy may offset the negative prognostic impact of close/positive surgical margins on outcome: an exploratory analysis from a phase III randomized trial by Italian Sarcoma Group and Spanish Sarcoma Group; 2) What's new in soft tissue tumors. 15-16/05/2012.
 24. POLISH SOCIETY OF SURGICAL ONCOLOGY ANNUAL MEETING 2012. Oral presentations: 1) The role of surgery in metastatic GIST; 2) Advances in surgical therapy of retroperitoneal sarcomas. 25/05/2012.
 25. AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING 2012. Oral presentation: Predicting Survival in primary resected retroperitoneal soft tissue sarcoma: a specific nomogram built on 3 major sarcoma center data sets. 01-05/06/2012.
 26. EUROPEAN SOCIETY OF MEDICAL ONCOLOGY (ESMO) ANNUAL MEETING 2012. Oral presentations: 1) The treatment of retroperitoneal sarcoma once the pathology is known; 2) STS Highlights. 28/09-02/10/2012
 27. CONNECTIVE TISSUE ONCOLOGY SOCIETY ANNUAL MEETING 2012. Program Chair. 14-17/11/2012.
 28. BRITISH SARCOMA GROUP ANNUAL MEETING 2013. Oral presentations: 1) Aggressive Fibromatosis: when would I operate; 2) Funding for sarcomas: an overseas view. 01-01-2013.
 29. EUROPEAN MULTIDISCIPLINARY CANCER CONFERENCE (EMCC) 2013 (ECCO-ESMO-ESTRO). Oral presentation: This house believes that metastasis should “not” be removed when CR is achievable in STS. 27/09-01/10/2013.
 30. SOCIETY OF SURGICAL ONCOLOGY ANNUAL MEETING 2014. Oral presentation: Post-relapse outcome in RPS treated by extended resection: biology trumps all. 14/03/2014.
 31. CZECH SARCOMA SOCIETY ANNUAL MEETING 2014. Oral presentation: Surgery of STS and Organization of Sarcoma Care in Italy. 03/04/2014.
 32. AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING 2014. Oral Presentation: Successes in Gastrointestinal Stromal Tumor: long-term considerations and survivorship. 30/05-03/06/2014.
 33. 47th ANNUAL MUSCULOSKELETAL TUMOR MEETING OF THE JAPANESE ORTHOPAEDIC ASSOCIATION 2014. Oral presentation: Surgery for Sarcomas. 17/07/2014.
 34. EUROPEAN SOCIETY OF MEDICAL ONCOLOGY (ESMO) ANNUAL MEETING 2014. Oral Presentation: Controversies in the neoadjuvant treatment of STS. 26-30/09/2014
 35. CONNECTIVE TISSUE ONCOLOGY SOCIETY ANNUAL MEETING 2014. Oral presentation: Malignancy grade and histologic subtype of primary retroperitoneal sarcoma (RPS) are predictive of pattern of recurrence: a large retrospective study from the Transatlantic RPS Working Group. 15-18/10/2014.
 36. GRUPO ESPANOL DE INVESTIGACION EN SARCOMAS ANNUAL MEETING 2014. Oral Presentation: Red line for resection in Retroperitoneal Sarcomas. 21/11/2014.
 37. SOCIETY OF SURGICAL ONCOLOGY ANNUAL MEETING 2015. Oral presentation: Soft Tissue Sarcoma Tumor Board: A Case-Based Discussion of Ongoing Controversies. 26-28/03/2015.
 38. SCANDINAVIAN SARCOMA GROUP ANNUAL MEETING 2015. Oral presentation: Current concepts and future perspectives for surgical treatment of visceral and retroperitoneal sarcomas. 21/05/2015.
 39. EUROPEAN CANCER CONGRESS 2015 (ECC 2015). Oral Presentation: Quality assurance in surgery. 25-29/09/2015.
 40. SOCIETY OF SURGICAL ONCOLOGY ANNUAL MEETING 2016. Oral presentation: Surgical Management of Soft Tissue Sarcomas: An Update on Current and Future Approaches. 03-05/03/2016.
 41. AUSTRALASIAN COLLEGE OF SURGEON - SURGICAL ONCOLOGY ANNUAL MEETING 2016. Oral

- Presentations: 1) Soft Tissue Sarcoma Of The Limb And Trunk: radiologic Planning And Extent Of Resection; 2) The Spectrum Of Fatty Tumours: interpretation Of Radiology And Extent Of Resection; 3) Retroperitoneal Sarcoma: Extent of Resection; 4) Fibromatosis: European Consensus For Management Of Desmoid And Peripheral Lesions. 03-04/05/2016.
42. AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING 2016. Oral presentation: Role of surgical resection in metastatic soft tissue sarcoma. 03-07/06/2016.
 43. TORONTO INTERNATIONAL SARCOMA SYMPOSIUM 2016. Oral Presentation: Desmoid-type fibromatosis: from aggressive local therapy to observation. When abstention is better care. 16/06/2016.
 44. EUROPEAN SOCIETY OF SURGICAL ONCOLOGY (ESSO) ANNUAL MEETING 2016. Oral Presentations: 1) Neoadjuvant treatment across tumor types: Sarcoma; 2) The timing of cytoreductive surgery for advanced GISTs. 14-16/09/2016.
 45. EUROPEAN SOCIETY OF MEDICAL ONCOLOGY (ESMO) ANNUAL MEETING 2016. Oral Presentation: Full-dose neoadjuvant anthracycline+Ifosfamide chemotherapy is associated with a RFS and OS benefit in localized high-risk adult STS of the extremities and trunk wall: an interim analysis of a prospective randomized trial. 08-10/10/2016.
 46. GRUPO ESPANOL DE INVESTIGACION EN SARCOMAS ANNUAL MEETING 2016. Oral Presentation: Multidisciplinary approach in clinical cases. 18/11/2016.
 47. BRITISH SARCOMA GROUP ANNUAL MEETING 2017. Oral Presentation: Neoadjuvant chemotherapy for Soft Tissue Sarcomas. 28/02-02/03/2017.
 48. ISRAELI SURGICAL ASSOCIATION 2017. Oral Presentation: What is new in abdominal sarcoma surgery? 09-12/05/2017
 49. POLISH SOCIETY OF SURGICAL ONCOLOGY ANNUAL MEETING 2017. Oral Presentation: Optimizing the approach to Retroperitoneal sarcoma: the case for a trans-atlantic collaboration. 18-20/05/2017
 50. JAPANESE ASSOCIATION OF SARCOMA TREATMENT AND RESEARCH ANNUAL MEETING 2018. Oral Presentation: Addressing the risk of localized extremity and retroperitoneal soft tissue sarcoma. 23-24/02/2018
 51. SOCIETY OF SURGICAL ONCOLOGY ANNUAL MEETING 2018. Oral Presentation: Microscopic Surgical Margins and Outcome in Localized GIST Treated within the EORTC Stbgs, Agtg, Unicancer, Fsg, ISG and Geis Randomized Trial On Adjuvant Imatinib. 22-24/03/2018
 52. 1st INDIAN SOFT TISSUE SARCOMA CONFERENCE 2018. Oral presentations: 1) Surgical Approach to primary retroperitoneal liposarcoma; 2) Advancing the knowledge of retroperitoneal sarcoma: present perspective and future directions of a global collaboration; 3) Pelvic Sarcoma and Desmoid-type Fibromatosis. 22-23/06/2018
 53. GRUPO ESPANOL DE INVESTIGACION EN SARCOMAS ANNUAL MEETING 2018. Oral Presentation: Multidisciplinary approach to STS Clinical Cases. 05/10/2018
 54. CONNECTIVE TISSUE ONCOLOGY SOCIETY ANNUAL MEETING 2018. Oral Presentation: Development of a Dynamic Prognostic Nomogram to Predict Overall Survival during Follow-Up in Primary Extremity Soft Tissue Sarcoma Patients Treated with Surgery. 15-17/11/2018
 55. SURGER - I - NNSBRUCK: SARCOMA AND NEUROENDOCRINE TUMORS 2018. Oral Presentation: What's the right surgery for abdominal/retroperitoneal sarcoma. 13-14/12/2018
 56. SOCIETY OF SURGICAL ONCOLOGY ANNUAL MEETING 2019. Oral Presentations: 1) Neoadjuvant strategies for retroperitoneal sarcoma; 2) Primary approach to resectable desmoid: operate or not operate. 28-30/03/2019.
 57. SCANDINAVIAN SARCOMA GROUP ANNUAL MEETING 2019. Oral Presentation: Surgical Challenges in Sarcoma of the Torso. 08-10/05/2019
 58. EUROPEAN MUSCULO-SKELETAL ONCOLOGY SOCIETY (EMSOS) ANNUAL MEETING 2019. Oral Presentation: Re-excision after unplanned excision: never. 15-17/05/2019
 59. AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING 2019. Oral Presentation: Neoadjuvant Chemotherapy in High Risk Soft Tissue Sarcoma. Final results of a randomized clinical trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG) and the Polish Sarcoma Group (PSG). 30/05-04/06/2019
 60. ASOCIACION ESPANOLA DE CIRUJANOS - I JORNADA NACIONAL DEL GRUPO DE TRABAJO TUMORES MESENQUIMALES 2019. Oral Presentation: Cirugia compartimental: Como la hago? Cuando esta indicada? 14/06/2019
 61. SWISS ONCOLOGY & HEMATOLOGY CONGRESS 2019. Oral Presentation: Soft Tissue Sarcoma: how can we cure more patients? 27/06/2019

- Clinical trials condotti

1. Localized High-Risk Soft Tissue Sarcomas of the Extremities and Superficial Trunk in Adults: an Integrated Approach Comprising 3 or 5 Cycles of Adjuvant Chemotherapy. A prospective controlled

- randomized trial from Italians Sarcoma Group and Spanish Sarcoma Group. **Principal Investigator**. Study accrual closed in 2007 (328 patients recruited). Reported at ASCO as oral presentation in 2010. Published in J Clin Oncol in 2012 and Ann Oncol in 2016
2. A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (YONDELIS®) in Patients with Localized Myxoid / Round Cell Liposarcoma. **Principal Investigator**. Study accrual closed in 2009 (30 patients recruited); reported at ESMO as oral presentation in 2009 and at ASCO as poster discussion in 2009. Published in Ann Oncol in 2012.
 3. Preoperative Chemo-Radiation Therapy in Retroperitoneal Soft Tissue Sarcomas (+ Radiation Boost). A multicentric phase II study from Italian Sarcoma Group. **Principal Investigator**. Study accrual closed in 2010 (86 patients recruited). Preliminary results reported at ASCO as poster discussion and at CTOS as oral presentation in 2011. Final results reported at ASCO in 2013 as poster discussion. Published in Eur J Cancer in 2014 and Ann Surg Oncol in 2017
 4. A Phase III Randomized Study Evaluating Surgery of Residual Disease in Patients with Metastatic Gastro-Intestinal Stromal Tuumor Responding to Imatinib Mesylate. A EORTC study (62063). **Principal Investigator**. Closed in advance for poor accrual in 2011 (12 patients recruited)
 5. Localized High-Risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults: an Integrating Approach Comprising Standard vs Histotype-Tailored Neoadjuvant Chemotherapy. **Principal Investigator**. Accrual started in 2011. Interim Analysis published in Lancet Oncol 2017; Final analysis presented as oral presentation at ASCO 2019
 6. A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma. A EORTC study (62092-22092). **Coinvestigator**. Accrual started in 2012. Final analysis presented at ASCO in 2019
 7. Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoids tumor patients: an observational study. **Principal Investigator**. Accrual started in 2013
 8. Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus RAdiotherapy in Soft Tissue Sarcoma patients (TRASTS). **Principal Investigator**. Accrual started in 2015. Phase I study published on EClinical Medicine in 2019.
 9. NBTXR3-301 - A multicenter randomized, open-label phase II/III study, to compare the efficacy of NBTXR3, implanted as intratumor injection and activated by radiotherapy, versus radiotherapy alone in patients with locally advanced soft tissue sarcoma of the extremity and trunk wall. **Coinvestigator**. Accrual started in 2016. Final analysis published on Lancet Oncology in 2019
 10. SACral Chordoma: a Randomized & Observational study on surgery versus definitive radiation therapy in primary localized disease (SACRO). **Principal Investigator**. Accrual started in 2017
 11. RETroperitoneal SARcoma Registry (RESAR): prospective collection of primary retroperitoneal sarcoma patient's data, radiological and pathological material for the TransAtlantic Retroperitoneal Sarcoma Working Group. **Principal Investigator**. Accrual started in 2017
- Attività di valutazione nell'ambito di procedure di selezione competitive nazionali ed internazionali
1. Membro del Conquer Cancer Foundation of American Society of Clinical Oncology (ASCO) Grants Selection Committee (GSC) 2019-2021

Data

06/09/2019

Luogo

Milano



4202322

PGEN/ U - 04/09/2019 - 0011257

Fondazione IRCCS Istituto Nazionale Tumori - Milano

SP: DS

Il sottoscritto Dott. Oliviero Rinaldi, in qualità di Direttore Sanitario della scrivente Fondazione,

- vista l'istanza del dott. Alessandro Gronchi nato a Livorno (LI) l' 11/06/1968 che ha richiesto il rilascio dell'attestazione relativa all'attività professionale svolta presso la scrivente Fondazione,
- visti gli atti di ufficio

Certifica

l'attestazione dell'attività professionale quali-quantitativa svolta dal Dott. Alessandro Gronchi sottoscritta dal dott. Roberto Salvioni Direttore del Dipartimento di Chirurgia e dal prof. Franco Valenza Direttore della s.c. Anestesia e Rianimazione (Blocco Operatorio).

Si rilascia la presente certificazione su richiesta dell'interessato per gli usi consentiti dalla Legge.

Il Direttore Sanitario
Oliviero Rinaldi

All.c.s.



Casistica operatoria Dr. Alessandro Gronchi 2010-2019

1978 interventi, 996 come primo operatore e 982 come assistente.

Tali interventi hanno comportato l'esecuzione di 5456 procedure, 2965 come primo operatore e 2491 come assistente.

In particolare ha eseguito:

- 918 interventi di resezione delle parti molli degli arti e del tronco superficiale, 397 come primo operatore e 521 come assistente
- 739 interventi di resezione multiviscerale per sarcomi/GIST addomino-pelvici e/o retroperitoneali, 480 come primo operatore e 259 come assistente
- 315 altri interventi di exeresi di sarcomi in altre sedi (testa/collo, torace, perfusione isolata d'arto, etc), 119 come primo operatore, 196 come assistente

Le procedure più comunemente effettuate in associazione alle resezioni dei tumori delle parti molli degli arti e del tronco superficiale sono state le seguenti:

- 258 ricostruzioni plastiche, 103 come primo operatore, 155 come assistente
- 290 ricostruzioni di parete mediante apposizione di materiale alloplastico, 90 come primo operatore e 200 come assistente
- 102 resezioni scheletriche, 44 come primo operatore e 58 come assistente
- 93 ricostruzioni vascolari, 48 come primo operatore e 45 come assistente

Le procedure più comunemente effettuate nel contesto delle resezioni multiviscerali per sarcomi/GIST addomino-pelvici e/o retroperitoneali sono state le seguenti:

- 404 nefrectomie radicali, 272 come primo operatore, 132 come assistente
- 211 emicolectomie dx, 137 come primo operatore, 74 come assistente
- 186 emicolectomie sx, 131 come primo operatore, 55 come assistente
- 149 splenectomie, 104 come primo operatore, 45 come assistente
- 143 pancreasectomie sx, 106 come primo operatore, 37 come assistente
- 142 resezioni del duodeno/ileo, 78 come primo operatore, 64 come assistente
- 103 resezioni gastriche, 56 come primo operatore, 47 come assistente
- 98 resezioni vascolari venose, 74 come primo operatore, 24 come assistente
- 96 resezioni del retto, 54 come primo operatore, 42 come assistente
- 76 resezioni osse di porzione di bacino o colonna, 44 come primo operatore e 32 come assistente
- 37 resezioni vascolari arteriose, 24 come primo operatore, 13 come assistente
- 35 resezioni epatiche parziali, 21 come primo operatore, 14 come assistente
- 19 duodenocefalopancreasectomie, 15 come primo operatore, 4 come assistente
- 15 isterectomie, 8 come primo operatore, 7 come assistente

IL RESPONSABILE
s.s. Controllo di Gestione
Dr. Giacomo Boscagli

Fondazione IRCCS
Istituto Nazionale dei Tumori
Prof. FRANCO VALENZA
CAPIVENE 65C03 Z404N

Fondazione IRCCS
Istituto Nazionale dei Tumori
Dr. Roberto Salvioni
C.B.: SLVART 52E11 F205V



Frances Wright MD MEd FRCSC
T2-057, 2075 Bayview Ave
Toronto, Ontario, Canada
M4N 3M5
Phone: 416-480-4210
Fax: 416-480-6002
Frances.Wright@sunnybrook.ca

September 9, 2019

Dear Promotions Committee:

I am delighted to write this **extremely strong letter of support** for Dr Alessandro Gronchi for his promotion to Full Professor.

I am the Program Director of the University of Toronto General Surgery Oncology Training Program. We are a fully accredited Surgical Oncology Program with the Royal College of Physicians and Surgeons of Canada. Our training program is also recognized by the American Council of Graduate Medical Education (ACGME) and by the European Surgical Oncology Examination Board. We have approximately 75 applicants from around the world and accept 4 trainees per year into our two-year program.

Our program initiated a relationship with the Fondazione IRCCS Istituto Nazionale dei Tumori - Milan in 2016 whereby the University of Toronto Surgical Oncology fellows can complete elective rotations at the Milan Cancer Institute. **We specifically chose to initiate this relationship with the Milan Cancer Institute because of its' international reputation and expertise in Sarcoma.** Dr Gronchi goes out of his way to ensure that the trainees have an outstanding experience and is the lead staff in Milan for our trainees.

Our trainees consistently comment that they have a **world class learning experience in Milan** and it is one of their highest yield rotations in terms of surgical education. I am personally delighted that these electives enhance the connections between University of Toronto and the Milan Cancer Institute as well as the Trans-Atlantic Retroperitoneal Sarcoma Working Group.

In summary, I am delighted to attest to Dr Gronchi's international reputation and expertise.

Please contact me if you need any further information,

Yours sincerely,

Frances Wright MD MEd FRCSC

Professor of Surgery, University of Toronto
Temerty Chair of Breast Surgery, Louise Temerty Breast Cancer Centre, Sunnybrook
Program Director of General Surgery Oncology Fellowship, University of Toronto
Quality and Knowledge Transfer Lead Cancer Care Ontario
Skin Cancer Lead, Cancer Care Ontario



**The Ottawa
Hospital | L'Hôpital
d'Ottawa**



**Carolyn Nessim Medicine Professional Corporation
Surgical Oncology / Chirurgie Oncologique**

General Campus Général

501 ch. Smyth Rd.
Room / Salle 1617d
Critical Care Wing / Aile de Soins Critique
Ottawa, ON
K1H 8L6

Carolyn Nessim MD, MSc, FRCSC, FACS

☎ 613-737-8899 ext/poste 71085

☎ 613-737-8659

✉ cnessim@toh.ca

To whom it may concern,

This letter attests that since January 2019 The Ottawa Hospital Complex Surgical Oncology Fellowship Program has been collaborating with the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan providing an elective rotation in Soft Tissue Sarcoma for our Surgical Oncology fellows. This rotation is under the supervision of Dr. Alessandro Gronchi and has been a great collaboration for our center. Thus far, we have sent one of our fellows already to do this excellent rotation. We hope to continue this collaboration and send more fellows for this elective rotation in the future.

Warmest regards,

Carolyn Nessim MD, MSc, FRCSC, FACS
Program Director Complex Surgical Oncology Fellowship Program
Surgical Oncologist - The Ottawa Hospital
Assistant Professor of Surgery - University of Ottawa
Clinician Investigator - Cancer Therapeutics Program - OHRI
501 Smyth Rd.
CCW 1617d, Box 202
Ottawa, ON, K1H 8L6
Phone: 613-737-8899 ext 71085
Fax: 613-737-8659
cnessim@toh.ca